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Abstract 
 Despite advances in medicine, antibiotic resistance threatens to return once preventable 
diseases to the human population.  The microbisporicins are 24-amino acid antibiotic peptides 
belonging to the lantibiotic class, which pathogens have been slow to develop resistance.  The 
uncommon post-translational modification S-[(Z)-2-aminovinyl]-D-cysteine (AviCys) is likely 
crucial to their activity, and appears in a small number of other peptides with compelling 
biological activities.  Total synthesis of an AviCys-containing peptide has eluded the chemical 
community. 
 The primary challenge of AviCys synthesis is the construction of a thioenamide 
functional group.  We demonstrate that acid-promoted reactions between an amide and acetal 
produce the desired Z-thioenamide.  We use mechanistic calculations to highlight the 
stereoelectronic control of this transformation, while careful examination of reaction byproducts 
helped us to optimize the yield and selectivity.  To this end, we developed a stereoselective 
method for Z-thioenamide generation in a model system. 
 While progressing to peptidyl thioenamide formation, we encountered an issue with the 
stereochemistry of our cysteine building block.  Examination of the diastereomeric products of 
reactions with our cysteine building bloack led us to conclude that it was racemic.  We used 
chiral HPLC and Mosher’s derivatization to determine the steps responsible for racemization.  
We redesigned the synthesis of the cysteine building block to produce enantiomerically enriched 
material. 
 Early attempts at thioenamide formation between amino acid derived coupling partners 
showed us that double protection of the α-amino amide amine was required.  The optimal amine 
x 
 
protection was as a tetrachlorophthalimide (Tcp).  We protected valinamide with Tcp and formed 
a thioenamide en route to the C-terminal ring of cypemycin, an AviCys-containing peptide with 
antileukemia activity.  Deprotection of the Tcp amine was achieved, under carefully controlled 
conditions, followed by coupling with Boc-leucine to form a tripeptide.  Liberation of the 
terminal acid and amine was achieved, though classic conditions for deprotection had to be 
tweaked for compatibility of the thioenamide functional group.  Macrocyclization was 
accomplished to form a Pht-capped cypemycin C-terminal ring. 
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Chapter 1. Introduction to Peptide Antibiotics and the Aminovinylcysteine 
Motif 
 
1.1. A Brief History of Antibiotics 
 The earliest antibiotic to be discovered from nature, mycophenolic acid (1), dates back to 
1893.  Bartolomeo Gosio, an Italian microbiologist, isolated this antibiotic from Penicilium 
glaucum as a crystalline solid.
1,2 
 In addition to being an antibiotic, mycophenolic acid also 
shows antifungal, antiviral, antitumor, and anti-psoriasis properties.
3
  A derivative of the 
compound is currently available to physicians, though as an immunosuppressant for transplant 
patients rather than an antibiotic.
4 
 
Figure 1.1. Early Antibiotic Discoveries 
 The world saw its first man-made antibiotic, arsphenamine (2), in the early twentieth 
century.  German scientist Paul Ehrlich synthesized the compound, based on cell-staining dyes 
(i.e., arsanilic acid).  His hope was to target cell walls, just as the dyes selectively stained them.  
He first proposed the concepts of chemotherapia specifica (chemotherapy) and zauberkugel 
(magic bullet), referencing sought-after specificity of therapeutics.
5
  In 1910, arsphenamine was 
approved as the premier treatment for syphilis, and would remain so for 40 years.
6
 
 No history of antibiotics would be complete without the discovery of penicillin in 1928, 
arguably the greatest breakthrough in medical history.
7
  In a now famously serendipitous turn-of-
events, scientist Alexander Fleming noticed a fungal contamination (later determined to be 
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Penicillium notatum, now P. chrysogenum) growing in one of his S. aureus cultures.  The fungus 
appeared to be killing the bacteria, so Fleming postulated that it must be secreting a bactericidal 
compound.  The compound was later isolated by Ernst Boris Chain and Norman Heatley and 
eventually used clinically in 1941.
8
  The immense potential of the compound was so apparent 
that the Anglo-American penicillin project was launched during World War II in an effort to 
isolate the compound in large enough quantities to aid the allied troops dying from infection 
overseas.
9,10 
 By 1945, penicillin was available to the public.  Fleming’s keen observation and 
curiosity generated a drug that has saved countless lives.   From the launchpad of the three 
exemplary discoveries described above, the library of antibiotics has expanded to more than 150 
compounds.
11
  Increased use of bactericidal (kills bacteria) and bacteriostatic (prevents bacterial 
growth) compounds has generated a number of highly resistant strains that threaten to make the 
impressive library irrelevant in the fight against infectious pathogens.     
1.2. Activity of Antibiotics and Bacterial Resistance 
 There have been four principal targets for antibacterial activity: 1) enzymes involved in 
cell wall biosynthesis, 2) nucleic acid metabolism, 3) protein synthesis, and 4) membrane 
disruption.  Dozens of compounds, manipulating one or more of these mechanisms, have been 
approved for clinical use.  Resistance in bacteria is also achieved through four fundamental 
methods: 1) drug alteration, 2) binding site alteration, 3) metabolic pathway alteration, and 4) 
increased efflux to the extra cellular space through increased activity of membrane pumps.  One 
or more of these strategies are active in resistant bacteria and must be circumvented in order to 
treat an infection.  The following section will describe some prototypical compounds, illustrating 
each mechanism of bactericidal activity, as well as how the four mechanisms of resistance have 
produced problematic bacterial strains. 
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1.2.1. Inhibitors of Cell Wall Biosynthesis:  β-Lactams - Drug Alteration 
 Beta-lactam antibiotics, such as penicillin, inhibit the synthesis of peptidoglycan (PG),  
thereby targeting  the biosynthetic pathway that produces cell wall.
12
  Bacterial cells constantly 
destroy and replace their cell wall, so inhibition of its synthesis leads to bactericidal activity.
13
  In 
beta-lactams this activity is achieved through mimicking the C-terminus of the natural peptide 
ligand of the D-Ala-D-Ala carboxypepsidase enzyme (Fig. 1.2).
14
  This enzyme is responsible 
for cross-linking of the peptidoglycan in the cell wall. The beta-lactam antibiotic binds 
irreversibly to the enzyme and prevents continuation of this process. 
 
Figure 1.2. Comparison of PG natural ligand and beta-lactam 
Resistance to penicillin was first mentioned in a report by Abraham and Chain, that 
described an enzyme capable of destroying the beta-lactam antibiotic.
15
  These enzymes were 
soon  named penicillinases, reflecting their high affinity and irreversible, covalent binding of this 
class of compounds.
16  
The nucleophilic alcohol side chain of an active-site serine residue opens 
the beta-lactam ring and covalently binds penicillin to the enzyme (Scheme 1.1).  Hydrolysis of 
this acyl-enzyme intermediate regenerates the enzyme and releases the inactive free di-acid 
derivative of penicillin.  This mechanism of resistance is representative of drug 
alteration/degradation and is also adopted by pathogens resistant to aminoglycosides, 
streptogramins, and lincosamide antibiotics.
17 
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Scheme 1.1. Mechanism of action of penicillinase 
1.2.2. Disruption of DNA Metabolism:  Quinolones - Binding Site Alteration 
Quinolone antibiotics, named for their aromatic core structure, achieve their bactericidal 
activity through inhibition of DNA duplication (nucleic acid metabolism).
18
  The quinolones act 
on gyrase and topoisomerase IV, two highly homologous enzymes responsible for aiding the 
unwinding, replication, and reunification of DNA during transcription.
19
   Crystal structures have 
shown that quinolones bind irreversibly to the enzymes.  
 
Figure 1.3. Ciprofloxacin (3), a quinolone antibiotic (quinolone core in red) 
Resistance to quinolone antibiotics has arisen through multiple of the four main 
mechanisms, with the most widely-studied being alteration of the gyrase and/or topoisomerase 
IV active site.  Mutations in genes lead to small changes in the DNA that encodes for the 
enzyme’s binding sites.  Several mutations have been observed but two are predominant in 
resistant bacteria: changes to a N-terminal tyrosine that is in the active site for DNA-binding and 
a change from serine to tryptophan in the site where quinolone binds.
20,21
  These mutated 
enzymes are still functional in terms of DNA transcription, but bind quinolone antibiotics 
relatively poorly. 
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1.2.3. Inhibitors of Protein Synthesis:  Tetracyclines - Increased Efflux 
The tetracyclines are a group of antibiotics that inhibit protein synthesis within bacterial 
cells.  These compounds are capable of binding to both rRNA and a subunit of the ribosome to 
inhibit translation.
22
  This dual action leads to their activity against a range of bacterial 
infections, viruses, and even protozoa.  The dominant mechanism of resistance towards 
tetracycline is an increased efflux of the drug out of the cell.
23
  A gene mutation codes for a 
transmembrane protein capable of pumping tetracycline out of the cell using a pH gradient.  This 
pump leads to minimal drug reaching the ribosome, or rRNA, and subsequently no activity.   
 
Figure 1.4. Tetracycline parent compound 
1.2.4. Membrane Disruption: Polymixins - Alteration of Transmembrane Lipids 
The polymixins are substantially higher molecular weight molecules relative to the 
previous examples given.  They are nonribosomal peptide antibiotics generated as part of the 
defense mechanism of rival bacteria.  Polymixins achieve bactericidal activity through binding to 
gram-negative cell membranes and creating pores through hydrophobic interactions.
24
  These 
peptide antibiotics are currently used as last resort drugs against multi-drug resistant infections 
caused by gram-negative bacteria.   
Polymixins can also be classified as cationic antimicrobial peptides (CAMPs), bearing a 
net positive charge.  Some bacteria have adapted to use electrostatic repulsion of their cell wall 
to achieve resistance.  Enzymes, in species of both Salmonella and Escherichia, have been 
identified that add positively charged 4-amino-4-deoxy-L-arabinose to their transmembrane 
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lipids.
25
  The modification prevents polymixins from binding to the membrane and forming the 
lethal pores. 
 
Figure 1.5. Colistin: a polymixin antibiotic 
 
Figure 1.6. Lipid IIB with 4-amino-4-deoxy-L-arabinose (red) attached 
 The above discussion is an attempt to illustrate some of the diversity of antimicrobial 
activity and the equally diverse methods that pathogens have developed to resist treatment.  
There are two million reports of resistant infections and 23,000 deaths per year as a result of 
untreatable infections.
26
    Antibiotic resistance will undoubtedly remain one of the most dire 
challenges for years to come and new treatments must be sought to combat the issue.  
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1.3. Lantibiotics 
 Lantibiotics derive their name from their antibiotic activity and the inclusion of the 
posttranslationally generated thioether bis-amino acids, lanthionine (6) and methyllanthionine 
(7).  Bacteria have been slow to develop resistance to lantibiotics, and some lantibiotics are 
effective against the most dangerous drug-resistant pathogens.   
 
Figure 1.7. Bis-amino acids of the lantibiotics 
1.3.1. Nisin 
The most widely studied lantibiotic is nisin (8), a 34-amino acid peptide with five 
lanthionine-bridged rings, that has been used in food preservation for more than 40 years.
27
  
Nisin has a broad range of antibiotic activity against gram-positive pathogens, achieving its 
bactericidal activity through two methods: pore formation in the cell membrane and inhibition of 
peptidoglycan formation.
28
  Though nisin resistance has been observed, the slow development 
and continued effectiveness of the lantibiotic highlights the difficulty that bacteria have 
circumventing the activity.
29
   
1.3.2. Microbisporicins 
More recently, the microbisporicins were isolated and characterized by Lazzarini et al.  
The group used a screening method designed to locate cell wall synthesis inhibitors that did not 
fall into the category of glycopeptides or β-lactams, classes of antibacterial molecules that have 
been met with significant microbial resistance.  The mixture contained two major congeners of a 
24-amino acid peptide.  A combination of peptides produced by the actinomycete Microbispora 
sp was patented in 2005, as the antibiotic 107891.
30
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Figure 1.8. Nisin (8) and definition of (methyl)lanthionine structure 
The mechanism of action of the microbisporicins was found to involve binding to lipid II 
and inhibition of cell wall biosynthesis in a fashion similar to conventional glycopeptide 
antibiotics such as vancomycin, an antibiotic commonly used in dire cases of resistant strains 
such as Clostridium difficile.
31
  However, microbisporicin does not bind to the D-Ala-D-Ala 
moiety of the lipid intermediate that vancomycin binds to; thus microbisporicin is non-
competitive with vancomycin.  Additionally, the microbisporicins show good to excellent 
activity against the most difficult infections to treat.  Against methicillin resistant S. aureus 
(MRSA), vancomycin intermediate resistant S. aureus (VISA), and Clostridium difficile (C. diff) 
the effectiveness is 
 
0.13, 2.0, and <0.125 µg/mL minimum inhibitory concentration (MIC) 
respectively.
32
  The ability to administer the lantibiotic concomitantly with vancomycin and the 
powerful therapeutic potential against problematic pathogens has generated much attention for 
the group of peptides as therapeutic agents. 
The two congeners characterized by Castiglione and Lazzarini (A1 and A2) differed in the 
level of hydroxylation at Pro-14 (Fig. 1.9).
30,32
 In 2014, Maffioli et al. reported that the 
lantibiotic can exist as a more complex mixture and characterized the additional congeners B0, 
B1, B2, F0, F1, and F2.
33
  These congeners varied in the level of hydroxylation at Pro-14, the 
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chlorination of Trp-4, the presence of a sulfoxide in the lanthionine A ring, and inclusion of an 
additional tripeptide, Gly-Pro-Ala, at the N-terminus.  They compared the activities of the 
various congeners and found that antibiotic potency increased with the level of hydroxylation at 
Pro-14 and the chlorination of Trp-4, and decreased upon oxidation of the thioether in the A-ring 
to a sulfoxide and addition of the three N-terminal amino acids (Fig. 1.9).  An additional 
variation, resulting from use of KBr the in growth medium, was characterized by Cruz et al. as a 
brominated tryptophan residue, rather than a chlorinated one.
34
 This family of related 
compounds, named NAI-108, shows a small increase in antibacterial activity relative to its 
chlorinated counterpart.  Cruz also identified congeners within NAI-108 that varied at the level 
of hydroxylation at Pro-14, labelling them A0, A1, and A2 corresponding to 0, 1, and 2 hydroxyl 
groups respectively.  
The microbisporicins contain an S-[(Z)-2-aminovinyl]-D-cysteine (AviCys) residue (Fig. 
1.9 and 1.10) at the C-terminus, i.e., a decarboxylated lanthionine derivative incorporated into 
the E-ring.  This structural motif is also found in other natural products, including the lantibiotics 
gallidermin
35
 and mersacidin,
36
 as well as some non-lantibiotics cypemycin
37
 and 
thioviridamide.
38
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Figure 1.9. Activity of microbisporicin congeners and comparison of sequence with 
planosporicin 
 
The AviCys-containing peptides isolated to-date have all displayed potent biological 
activities, including anticancer,
37
 prophylactic,
39
 and antibacterial.
30
  The importance of the 
AviCys residue is highlighted by a comparison of the lantibiotics, planosporicin and the 
microbisporicins (Fig. 1.9 and 1.10).  The peptides have highly homologous sequences, but 
planosporicin has a C-terminal acid and a regular lanthionine residue instead of AviCys in the E-
ring.  Against most bacterial strains, planosporicin is two orders of magnitude less effective vis-
à-vis bactericidal activity, when compared with the major A1 and A2 variants of the 
microbisporicins.
32
  The aim of my graduate research has been the synthesis of AviCys-
containing macrocycles and their incorporation into natural products.  The two natural products 
that inspire this research are the lantibiotic microbisporicins and the linaridin, cypemycin. 
11 
 
 
Figure 1.10. C-terminal AviCys containing peptide macrocycles 
1.4. Cypemycin 
 Cypemycin (Fig. 1.11) was isolated from Streptomyces sp. OH-4156 by Omura and 
coworkers in 1993.
37  
  The compound showed both promising cytotoxic activity against 
leukemia cells (IC50 1.3 μg/mL) and antibiotic activity against Micrococcus luteus (MIC 0.2 
μg/mL). The peptide structure was determined the following year by the same group.  
Cypemycin is a 21-amino acid peptide with an N,N-dimethylalanine residue at the N-terminus, 
several dehydrobutyrines, and an AviCys (Fig. 1.11).
40
 
 
Figure 1.11. Cypemycin (14) 
12 
 
 The AviCys-containing macrocycles of the microbisporicins and cypemycin are the same 
size ring (13 atoms), but the cypemycin ring presents less of a challenge in terms of the chemical 
synthesis.  The C-terminal macrocycle of the microbisporicins is interlocked with an additional 
thioether ring, greatly increasing the difficulty of synthesis (Figure 1.12).  Early attempts, 
discussed in Chapter 2, on the synthesis of a microbisporicin AviCys analog were unsuccessful.  
The cypemycin ring serves as a valuable synthetic target and a simplified system to explore the 
synthesis of the AviCys post-translational modification. 
 
Figure 1.12. Comparison of microbisporicin DE ring system and cypemycin C-terminal ring 
1.5. Biosynthesis of AviCys and AviMeCys 
Biosynthesis of AviCys and AviMeCys occurs necessarily at the C-terminus of the 
peptide and is catalyzed by a family of enzymes called homo-oligomeric flavin-containing 
cysteine decarboxylases (HFCD).
41-45  
These enzymes generate a thioaldehyde (RCH=S) in the 
side chain of the C-terminal cysteine.  A flavin cofactor is involved in an oxidative 
decarboxylation (Step I), producing a reactive enethiolate anion (Scheme 1.2).  This anion 
attacks, in a Michael addition, at a dehydroalanine (Dha) or a dehydrobutyrine (Dhb) upstream in 
the peptide (Step II) and forms the AviCys or AviMeCys residue respectively (Step III). Once 
post-translational modifications of the prepeptide are complete, an N-terminal leader peptide is 
cleaved and the mature peptide is transported out of the cell. 
13 
 
 
Scheme 1.2. Conceptualizing AviCys and AviMeCys biosynthesis 
1.6. Previous Chemical Approaches to AviCys 
VanNieuwenhze and coworkers described a pseudo-biomimetic approach involving 
decarbonylation of a thioester to give the necessary unsaturation.
46,47
  The method relies on the 
installation of a thioester that is eliminated under metal catalysis.  They were able to achieve 
high yields in simple systems (Scheme 1.3). 
 
Scheme 1.3. VanNieuwenhze's thioenamide synthesis 
However, when a model peptide 17, mimicking the D-ring AviMeCys functionality of 
mersacidin, was subjected to the optimized conditions, the yield dropped drastically, albeit the 
reaction proceeded with favorable stereoselectivity (Scheme 1.4, equation I).  When modified 
conditions were applied to the decarbonylation of the cyclic peptide 19 (Scheme 1.4, equation 
II), VanNieuwenhze and coworkers were able to achieve only a modest 30% yield.  These 
conditions are promising, but low yields and the requirement for preformed lanthionines with 
suitable leaving groups makes incorporation into total synthesis a challenge.  
14 
 
Scheme 1.4. VanNieuwenhze synthesis of mersacidin D-ring analog 
Castle and co-workers reported a method for thioenamide formation in 2010 by way of a 
thiyl radical reacting with a terminal ynamide.
48
  They found that E/Z-selectivity could be 
controlled by reaction conditions (Scheme 1.5).  Their examples showed that the product 
distribution was determined thermodynamically (path I) if the reaction was allowed to run long 
(2.5-6 h) and with excess thiol.  These conditions led to the E isomer (J = 13.6 Hz) in as high a 
ratio as 33:1 with thiophenol (Scheme 1.5, R
3
 = Ph). 
 
Scheme 1.5. Castle's method employing radical addition 
However, kinetic control (path II) could be achieved with brief reaction times and a single 
equivalent of thiol.  These conditions led to reliable production of the Z-thioenamide (J = 7.9 Hz 
for olefinic protons) in good yield with Z:E ratios as high as 11:1 in the case of n-butanethiol 
(Scheme 1.5, R
3
 = 
n
Bu).  Castle makes note of a single example of an exceptionally bulky thiol, 
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t
BuSH, in which both sets of reaction conditions led to the Z product exclusively in reduced yield 
(41%).         
In an attempt to place this method within the broader scope of peptide chemistry, Castle’s 
group demonstrated that the control of E/Z selectivity translates well to cysteine-derived thiols 
(Scheme 1.6).  While the ability to control which isomer is generated makes this an appealing 
method, the radical mechanism makes it troublesome in the context of complex peptides.  Only 
tertiary ynamides were used in the study, presumably due to unwanted side reactions resulting 
from homolytic cleavage of the nitrogen-hydrogen bonds in non-tertiary amides.  Additionally, 
there were no amino acid derived amides used in this study. Further functionalization of the 
amide nitrogen, aimed at producing peptidyl products, presents a significant challenge.  No 
further reports have appeared from the Castle Group in this area.   
The approaches of Castle and VanNieuwenhze described above are the only two 
published efforts at thioenamide synthesis with the aim of natural product peptides.  While both 
methods have their benefits, a range of complementary approaches is often required to achieve 
total synthesis.  The paucity of methods to generate AviCys hints at the considerable challenges 
in the formation of this unique and biomedically important functional group. 
 
Scheme 1.6. Castle's thioenamide synthesis 
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Chapter 2. Acid-Promoted (Thio)Enamide Formation  
2.1. Acid-Mediated (Thio)Enamide Formation 
We envisioned an alternative approach to thioenamide formation consisting of 
condensation of an amide with an acetal followed by elimination (Scheme 2.1).  Despite the first 
report of such a reaction as early as 1953,
1
 there are very few examples in the literature since and 
the influence of the substrate structure on the stereochemical outcome was unstudied.   
 
Scheme 2.1. Generic acid-mediated thioenamide formation 
Two examples encouraged us to believe that we could achieve the desired cis 
stereochemistry through electronic effects (Scheme 2.2).
2,3 
 The noteworthy difference in the 
work of Baxter, relative to that of Estevez, is a β-sulfur substituent, which reverses the 
stereoselectivity of the reaction.
 
 
Scheme 2.2. Precedent for influence of b-substituent on stereochemical outcome 
We hypothesized that the sulfur atom influences the transformation to be Z-selective 
through a preferred conformation with inherent gauche interactions between the electronegative 
atoms during the elimination step.
4
  Anti elimination from this conformation would yield 
selectively the cis product (Scheme 2.3). 
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Scheme 2.3. Originally proposed mechanism for Z-enamide formation 
2.2. Early Design of a Tripeptide Substrate for Thioenamide Formation 
 At the outset it was ambitiously envisioned that the key reaction would take place via an 
intramolecular reaction in a preformed tripeptide (Scheme 2.4).  This strategy would allow us to 
perform the more pedestrian reactions such as amine and carboxylic acid deprotection as well as 
peptide bond formation before generation of our thioenamide.  Additionally, the ring strain of 
potential transition states during thioenamide generation/cyclization would reinforce our desired 
cis stereochemistry about the olefinic bond.     
 
Scheme 2.4. Retrosynthetic analysis of the E-ring of microbisporicin 
To study the macrocyclization reaction, a tripeptide was designed that would mimic the 
amino acid sequence found in the microbisporicin E-ring (Scheme 2.4 and Figure 2.1) but would 
not introduce the complexities of the larger peptide.  This required:  
(a) a cysteine bearing an acetal-functionalized side chain;  
(b) N-terminal protection that reduces the nucleophilicity of the N-terminal amine and 
thus  prevents competing reaction with acetal;  
(c) an amide at the C-terminus; and  
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(d) alaninamide (H-L-Ala-NH2) to be used as a substitute for H-L-Cys-NH2 to reduce 
complexity relative to the native sequence 
 
Figure 2.1. Model tripeptide for initial studies 
2.3. Synthesis of the Acetal-Functionalized Cysteine Residue  
  Cysteine building block 28 (Figure 2.2) was designed to fulfil our criteria.  An allyl 
group was chosen for protection of the carboxylic acid due to the non-acidic conditions used in 
cleavage.   
 
Figure 2.2. Acetal-modified cysteine 
A dimethoxy acetal was chosen due to commercial availability of starting materials and based on 
the work of Carter and Mash in which a  thioenamide was formed intramolecularly (Scheme 
2.5).
5
  This example shows that even a secondary amide can react in high yields in the context of 
a 6-membered  ring.   Based on this precedent, a phthalimido group was chosen for divalent 
amine protection.  
 
Scheme 2.5. Thioenamide formation by Carter and Mash 
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The first task involved replicating and optimizing the work of a previous group member, 
Katie Moreaux.  Synthesis of the requisite cysteine derivative began with commercially available 
Fmoc-D-Cys(Trt)-OH (31).  Treatment with cesium carbonate and allyl bromide afforded allyl 
ester 32 in good yield (Scheme 2.6).  This was followed by deprotection of the amine using 
diethylamine and reprotection with phthalic anhydride, assisted by triethylamine.  Originally, 
Fmoc removal was performed using piperidine and the free amine purified before reprotection.  
However, it was found that amine deprotection using the more volatile diethylamine eliminated 
the need for purification before reprotection and resulted in better overall yields of cysteine 
derivative 33.  Detritylation of the side chain thiol using trifluoroacetic acid and triethylsilane as 
a trityl cation scavenger gave free thiol 34.  Monitoring the deprotection was difficult due to the 
trityl ether 33 and the free thiol 34 being indistinguishable via TLC.  The reaction progress 
needed to be monitored via 
1
H NMR, observing the generation of the thiol proton as a doublet of 
doublets at 1.54 ppm.  Alkylation of the thiol was accomplished in mediocre yield using cesium 
carbonate and 2-bromo-1,1-dimethoxyethane to render target building block 28.   
 
Scheme 2.6. Synthesis of suitably protected cysteine 
The low yield of the alkylation can be partly attributed to the formation of the dimeric 
side product 36 whose structure was confirmed by X-ray crystallography (Scheme 2.7).  This 
side product is likely the result of dehydroalanine formation followed by 1,4-addition of a 
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thiolate anion.  Unfortunately, extensive attempts to optimize the alkylation reaction further were 
unsuccessful. 
 
Scheme 2.7. Mechanism for formation of dimerization side product 36 in S-alkylation reaction 
2.4. Model Tripeptide Synthesis 
Acetal-bearing cysteine 28 was incorporated into the model tripeptide system required for 
the intramolecular formation of AviCys (Scheme 2.8).  Selective deprotection of the allyl ester 
was accomplished using catalytic palladium (0).  Free acid 37 was activated as its N-
hydroxysuccinimide (NHS) ester, followed by coupling with L-phenylalanine.  The dipeptide 
acid was then coupled with alaninamide to give the desired tripeptide 39.  The transformation 
from free acid 37 to tripeptide 39 was accomplished in 65% yield over two steps, but analysis by 
HPLC revealed the presence of at least three distinct compounds, inseparable by flash 
chromatography.  These compounds were each found to have the same mass by LC-MS.  We 
explored a different approach to tripeptide 39 in the hope that this would give a single product.         
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Scheme 2.8. Synthesis of model tripeptide 
A second approach to tripeptide formation proved more effective (Scheme 2.9).  
Coupling of Fmoc-Phe-OH (40) and alaninamide (41) afforded an Fmoc-protected dipeptide 
(42), albeit in low yield.  Deprotection of the amine to give dipeptide 43 and coupling with 
cysteine building block 37, led to the desired tripeptide (39) in good yield, although the HPLC 
trace of this material still revealed two major compounds (with the same M
+
), which were again 
not separable by flash chromatography.  While we were not able to achieve homogenous 
tripeptide, it proved to be the preferred method for tripeptide formation.   
 
Scheme 2.9. Second Generation synthesis of tripeptide 
 We next attempted the intramolecular dehydrative condensation/cyclization of model 
tripeptide 39 (Scheme 2.10).  Most often, mixtures of the two isomeric species of 39 were used 
for cyclization studies.  Following literature examples, a protic acid (TFA or pTsOH) in an 
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aromatic solvent (benzene or toluene) was used to promote the desired reaction.
2,3
  
Unfortunately, significant degradation occurred and neither starting material 39 nor desired 
product 44 was ever isolated from the reaction mixture.  It was clear that our proposed 
mechanistic pathway for thioenamide generation needed to be better understood in order to 
achieve a useful transformation in practice.   
 
Scheme 2.10. Intramolecular AviCys formation 
2.5. Mechanistic Investigations  
Inspired by the examples in Scheme 2.2, we studied the mechanistic basis for the 
stereochemical phenomenon in regard to acid-mediated, stereoselective Z-thioenamide 
formation.  Computational studies were performed, in collaboration with Visal Don 
Subasinghege and Dr. Revati Kumar, for the two simplified substrates shown in Scheme 2.11 on 
the pathway of the reaction mechanism.  
The thioether, in the β-postition relative to the acetal, is instrumental in determining the 
stereochemical outcome.  The two electronegative groups at Cα will favor a gauche relationship 
with the Cβ-S substituent, promoting anti-elimination from the conformer drawn in step VI 
(Scheme 6, A).
4
  In the absence of an electronegative β-substituent the energy difference between 
the relevant conformations is reduced allowing sterics to play a much larger role and likely 
favoring the E-product. 
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Scheme 2.11. A. Proposed mechanism for thioenamide formation; B. Variations revealed by 
calculations 
 
Relative energies of reactants, transition states and products were determined for Steps I-
VI.  Steps I and II were found to be concerted.  Step III displayed no unexpected behavior.  Steps 
IV and V were also found to be concerted and, indeed, to proceed further to a delocalized 
cationic species (Step Vb).  Stabilization is observed by donation of the lone pair of the nitrogen 
into the empty p-orbital, as shown in Scheme 2.11B. 
The two series showed minimal variations in energetics and no difference in orientations 
until Step VI. The intermediacy of a carbocation in both cases is suggestive of an E1-like 
mechanism.  At this key juncture in the calculations, methylamine was used as a base to assist 
proton abstraction: the intermediate cation derived from acetal 45 loses a proton, with no 
transition state, leading rapidly to the E-isomer.  In contrast, for this step in the reaction of 46, 
there is a discernable transition state in which there has been rotation about the C-C bond, 
leading to a conformation in which the transition state is stabilized, by an additional 4.04 kcal 
mol
-1
, by hyperconjugative donation from the σ-orbital of the C-H bond into the σ*-orbital of the 
adjacent C-S bond. This is consistent with our original hypothesis that there is a rotational barrier 
to elimination, leading to a hyperconjugative stabilization of electronegative substituents.  
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Interestingly, Natural Bond Orbital (NBO) analyses
6
 revealed a partial positive charge on the 
sulfur atom of the final product 48. This charge generates an electrostatic attraction with both the 
oxygen and the nitrogen of the newly formed enamide, stabilizing the Z-isomer by 1.8 kcal mol
-1
 
relative to the E-isomer.  More details on these calculations can be found in our published work.
7 
 
Figure 2.3. Energy profile diagram for step VIa 
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2.6. Condensations with Acetamide 
With insight from our computational studies we began condensations using previously 
prepared cysteine 28 and acetamide (Scheme 2.12), by analogy to both Baxter’s work and with 
insight from our modeled reactions. 
 
Scheme 2.12. General acetamide condensation 
Experiments began with equimolar amounts of cysteine building block 28 and 
pTsOH.H2O.  Baxter employed an acetal concentration of 1 mg/mL in benzene, and this also 
worked well for our study.  Attempts to raise the overall reaction concentration resulted in lower 
yields.  The anticipated products, Z- and E-49, were isolated in a 4:1 ratio; Z-49 could be isolated 
pure in 40% yield (Scheme 2.13).  This assignment of stereochemistry is based on the coupling 
constants for the olefenic protons: 7.4 Hz (Z) and 13.6 Hz (E).
 8,9,10
 
 
Scheme 2.13. Condensation of 28 with acetamide 
A minor product of the reaction mixture was vinyl methyl ether 50 (16%), resulting from 
premature elimination of methanol from the oxocarbenium intermediate (Scheme 2.14, path A).  
The assignment of this structure was made based both on the 
1
H NMR peak at 3.54 ppm (methyl 
ether) as well as the trans-olefinic protons at 5.28 and 6.72 ppm split only once each, with a 
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coupling constant of 10.0 Hz. Additionally, bis-amide 51 arising from two sequential additions 
of acetamide (Scheme 2.14, path B), could be observed in trace amounts, as evidenced by mass 
spectrometry. 
 
Scheme 2.14. Formation of enol ether and bis-amide side products and pertinent spectroscopic 
data 
 
Interestingly, the E-isomer was difficult to obtain pure and equilibrated to a mixture of E- 
and Z-isomers, upon standing, even at low temperature.  Harada et al. previously reported 
conversion of carbapenam antibiotics containing E-thioenamide side chains, to the corresponding 
Z-isomers (Scheme 2.15).
11
  Starting with 52, an E-thioenamide-containing carbapenem isolated 
from nature, they were able to shift the position of the E/Z equilibrium significantly  using 
quaternary ammonium halide salts at reflux in chloroform.  The optimal ammonium salt for this 
conversion was tetraoctyl methyl ammonium chloride (TOMAC), converting the material to the 
cis isomer in 92% yield.   
 
Scheme 2.15. Harada's conversion to cis-thioenamide 
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Deuteration of the carboxylic acid before isomerization (Scheme 2.16) led to 84% deuterium 
incorporation at the olefinic position adjacent to the sulfur, leading Harada et al. to conclude that 
proton exchange takes place intramolecularly.  Using this information, they proposed the 
mechanism in Scheme 2.16 whereby the nitrogen lone pair stabilizes a positive charge in the pi 
system as the pi electrons abstract the acidic proton of the carboxylic acid.  
 
Scheme 2.16. Harada's proposed mechanism of isomerization 
With a view to employing more synthetically valuable amides in the future, we scaled 
back to a stoichiometric amount of acetamide.  This led to the formation of 2:1 adduct 54 
(Scheme 2.17A), in 81% yield, testifying to the increased nucleophilicity of the enamide 49 over 
acetamide.  The 
1
H NMR spectrum indicated two distinct coupling constants for the two sets of 
olefinic protons, 14.6 and 11.4 Hz.  The second elimination appears to be under steric control, 
affording the E-enamide.  If the reaction was allowed to run overnight, under these conditions, 
N-acyl pyrrole 55 could be isolated in 38% yield.  The identification of the pyrrole structure was 
consistent with aromatic signals in the 
1
H NMR spectrum at 6.25, 7.14, and 7.25 ppm, and with 
splitting patterns characteristic of pyrroles substituted at the 2-position.  We propose that the 2:1 
adduct undergoes pericyclic ring closure followed by a thermal rearrangement, analogous to a 
transformation reported by Kurita et al. (Scheme 2.17B).
12
  
32 
 
 
Scheme 2.17.  A. Mechanism for formation of pyrrole 51 from 2:1 adduct 54 B. Analogous 
mechanism proposed by Kurita 
 
We investigated a range of acids vis-à-vis our desired transformation.  A key advance 
was the discovery that a Lewis acid, boron trifluoride diethyl etherate, was effective.  Catalytic 
and equimolar amounts of BF3.OEt2 were insufficient to produce the desired product in useful 
amounts.   When the number of equivalents of Lewis acid was increased to five, consumption of 
starting material occurred rapidly and the yield increased beyond that achieved with protic acids 
(e.g., pTsOH and TFA).  Elimination of the second equivalent of methanol occurs more quickly 
and the vinyl ether does not form at all under these conditions.  Product formation occurs in 40-
45% with a 5:1 Z:E ratio in only 40 minutes but further reaction/degradation of the product is 
observed if the reaction is continued longer.    While the reaction time and yield of desired 
product were improved with BF3·Et2O, only trace amounts of known side products were 
observed via crude 
1
H NMR and no starting material was recovered.   
In an attempt to modulate the ratio of desired reactivity versus degradation, a milder 
Lewis acid was studied.  Boric acid is a remarkably inexpensive reagent (~11¢/g) that has been 
used by Harichandran et al. to catalyze the generation of bis-amides (Scheme 2.18).
13
 They 
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showed that bis-amides could be formed from a range of aldehydes and amides with only 15 
mole percent boric acid in toluene.  
 
Scheme 2.18. Harichandran's aromatic bis-amide formation 
As expected, boric acid was not acidic enough to activate acetal 28, in our case, and only 
trace amounts of product were formed.  Revealing aldehyde 56 prior to 
condensation/dehydration (Scheme 2.19) serves two purposes: elimination of the potential 
methyl vinyl ether side product and lowering the required acidity to promote the desired reaction.  
When aldehyde 56 was reacted with acetamide and boric acid in benzene, the desired Z-product 
was isolated in 21% yield along with recovered aldehyde starting material 56 (31%) and bis-
amide 51 (35%).   
 
Scheme 2.19. Reaction of aldehyde 56 with acetamide and boric acid in benzene 
Chen et al. heated bis-amides in DMSO to convert them to their corresponding enamides 
(Scheme 2.20A).
14
 Schneider et al. investigated a simple two component system (Scheme 2.20B) 
on their way towards three component amido substitution using amides and aldehydes.
15
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Scheme 2.20. Enamide formation 
They found that bis-amide formation occurs rapidly at room temperature, but elimination occurs 
rapidly to generate the enamide at temperatures above 35 °C. We leveraged these facts and 
changed our solvent to toluene to simultaneously decrease the formation of bis-amide and 
increase reactivity to consume all the aldehyde.  It was found that commencing the reaction with 
a single equivalent of acetamide, and adding additional equivalents over time also reduced the 
formation of bis-amide.  With these modifications to the method, the yield of desired product 
was increased to 57% with an isolated Z:E ratio of 8:1 (Table 2.1).  These optimized conditions 
are summarized with some of the other conditions investigate in Table 2.1.   
Table 2.1. Thioenamide formation 
 
 Reaction Conditions Z-49 E-49 56 50 51 
1 
Protic acid (TFA or pTsOH), benzene, 
80 °C, 4 h 
40% 10% 0% 16% trace 
2 
Boron trifluoride, benzene, 80 °C, 45 
min 
45% 8% 0% 0% 0% 
3 Boric acid, benzene, 80 °C, 5 d 21% 
not 
isolated 
31% N/A 35% 
4 Boric acid, toluene, 111 °C, 2 d 57% 6% 0% N/A 0% 
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We speculate that the increase in desired reactivity with Lewis acids is the result of their 
ability to coordinate to both the amide nucleophile and the aldehyde electrophile.  Protic acids 
lack this ability to generate a six-membered ring transition state template for the transformation 
(Figure 2.4). 
 
Figure 2.4. Coordinated transition state with Lewis acid 
In summary, we described a new chemical approach to the synthesis of Z-thioenamides 
that involves condensation of an aldehyde and amide under mild, Lewis acidic conditions at 
elevated temperatures.  Based on stereoelectronic predictions, and supported by computational 
insights into the mechanism of the addition-elimination reaction, the approach capitalizes on 
sulfur’s electronic properties to steer the reaction via a mechanism whereby it further supports a 
preferred conformation that leads to stereoselective formation of the Z-product.  Careful 
manipulation of reagents and reaction conditions subsequently led to an increase in yield and 
stereoselectivity of the desired reaction.  
2.7. Experimental Procedures 
2.7.1. General Methods  
All reactions were performed under a dry nitrogen atmosphere unless otherwise noted.  
Reagents were obtained from commercial sources and used directly; exceptions are noted.  
Diethylamine and triethylamine were dried, distilled from CaH2, and stored over KOH pellets.  
Flash chromatography was performed using flash silica gel (40-63 µ) from Aldrich Inc.  
Reactions were followed by TLC on pre-coated silica plates (200 µ, F-254, from Merck Inc.).  
The compounds were visualized by UV fluorescence or by staining with KMnO4, iodine, or 
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ninhydrin.  HPLC was performed on a Waters 600 system, interfaced with Empower™ software, 
and equipped with a Waters 2487 UV detector, monitoring absorption at 218 and 254 nm. All 
columns were 250 mm long. Analytical work was conducted on 4.6 mm diameter columns with a 
flow rate of 1 mL min
-1
: Daicel® Chiralcel OD-H (chiral), Econosil® silica 10 μ (normal phase), 
or Altima® C18 10 μ (RP). Semi-preparative RP work was conducted on a 10 mm diameter 
Altima® C18 10 μ column with a flow rate of 3 or 4 mL min
-1
.  Eluents for HPLC work are 
detailed in each procedure.  Nuclear Magnetic Resonance spectra were recorded on a Bruker 
AV-400 Nanobay or a Bruker AV-500 Prodigy liquid spectrometer.  Proton NMR data is 
reported in ppm downfield from TMS as an internal standard or calibrated on solvent peaks.  
High resolution mass spectra were recorded using an Agilent 6210 time-of-flight mass 
spectrometer with electrospray ionization. 
2.7.2. Synthesis of cysteine building block 28 (Scheme 2.6) 
Fmoc-D-Cys(Trt)-OAll (32). Allyl bromide (130 µL, 182 mg, 1.50 mmol, 1.0 equiv.) and 
Cs2CO3 (244 mg, 0.749 mmol, 0.5 equiv.) were added to a solution of Fmoc-D-Cys(Trt)-OH 
(31) (869 mg, 1.484 mmol, 1.0 equiv.) in DMF (7 mL).  The mixture was stirred overnight at rt 
under N2.  The mixture was diluted with EtOAc (100 mL) and washed with water (50 mL).  The 
aqueous layer was extracted a second time with EtOAc (50 mL) and the organic layers 
combined, washed with brine (50 mL), filtered through MgSO4, and concentrated.  The residue 
was subjected to flash chromatography, eluting with 5:1 hexanes-EtOAc to isolate 32 as a 
colorless solid (856 mg, 92%). Rf 0.25 (4:1 hexanes-EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 
2.52-2.75 (m, 2H), 4.22 (t, J = 6.6 Hz 1H), 4.29-4.42 (m, 3H), 4.54-4.67 (m, 2H), 5.19-5.34 (m, 
1H), 5.24 (d, J = 10.8 Hz, 1H), 5.29 (d, J = 16.8 Hz, 1H), 5.80-5.93 (m, 1H), 7.15-7.32 (m, 11H), 
7.36-7.43 (m, 8H), 7.60 (d, J = 5.4 Hz, 2H), 7.75 (d, J = 6.4, 2H); 
13
C NMR (100 MHz, CDCl3) δ 
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34.2, 47.2, 53.1, 66.4, 67.2, 67.3, 118.9, 120.1, 125.2, 127.0, 127.2, 127.8, 128.2, 129.6, 131.5, 
141.4, 143.9, 144.0, 144.4, 155.7, 170.3. HRMS (ESI) calcd for C40H35NNaO4S (M+Na)
+
: calcd 
648.2179; obsd 648.2178.  
Pht-D-Cys(Trt)-OAll (33). Diethylamine (10 mL) was added to a solution of Fmoc-D-Cys(Trt)-
OAll (32) (1.476 g, 2.36 mmol, 1.0 equiv.) in acetonitrile (10 mL).  The mixture was stirred 
under N2 for 2 h at rt.  The solution was concentrated and the residue dissolved in toluene (15 
mL).  To this mixture was added phthalic anhydride (350 mg, 2.36 mmol, 1.0 equiv.) and 
triethylamine (658 µL, 480 mg, 4.72 mmol, 2.0 equiv.).  The mixture was heated at reflux under 
Dean-Stark conditions for 16 h.  The mixture was concentrated and the residue purified by flash 
chromatography eluting with 3:1 hexanes-ethyl acetate to isolate 33 as a colorless solid (1.079 g, 
86%). Rf 0.45 (2:1 hexanes-EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 3.02 (dd, J = 13.6, 4.5 Hz, 
1H), 3.39 (dd, J = 13.6 Hz, 11.2 Hz, 1H), 4.42 (dd, J = 11.2, 4.5 Hz, 1H), 4.45-4.55 (m, 1H), 
5.10-5.16 (m, 2H), 5.67-5.78 (m, 1H), 7.19 (t, J = 7.2 Hz, 3H), 7.22-7.28 (m, 6H), 7.38 (d, J = 
7.4 Hz, 6H), 7.70 (dd, J = 5.4, 3.0 Hz, 2H), 7.82 (dd, J = 5.4, 3.0 Hz, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ 30.9, 51.9, 60.5, 66.4, 67.6, 118.5, 123.7, 126.9, 128.1, 129.7, 131.3, 131.8, 134.3, 
144.4, 167.3, 167.7. HRMS (ESI) calcd for C33H27NNaO4S (M+Na)
+
: calcd 556.1553; obsd 
556.1566.        
Pht-D-Cys(H)-OAll (34). Trifluoroacetic acid (75 µL, 0.985 mmol, 5.0 equiv.) and triethylsilane 
(152 µL, 0.985 mmol, 5.0 equiv.) were added to a solution of Pht-D-Cys(Trt)-OAll (33) (105 
mg, 0.197 mmol, 1.0 equiv.) in CH2Cl2 (7 mL) at 0 °C.  After 10 min, the mixture was allowed 
to warm to rt was stirred under N2 for 2 h at rt.  The mixture was concentrated and the residue 
purified by flash chromatography eluting with 5:1 hexanes-ethyl acetate to isolate 34 as a 
colorless oil (51 mg, 0.175 mmol, 89%). Rf 0.25 (4:1 hexanes-EtOAc). 
1
H NMR (400 MHz, 
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CDCl3) δ 1.54 (dd, J = 9.6, 8.1 Hz, 1H), 3.29-3.50 (m, 2H), 4.67 (d, J = 5.7 Hz, 2H), 4.97 (dd, J 
= 10.4, 5.2 Hz, 1H), 5.24 (dd, J = 10.5, 1.1 Hz, 1H), 5.29 (dd, J = 17.2, 1.3 Hz, 1H), 5.82-5.92 
(m, 1H), 7.78 (dd, J = 5.4, 3.0 Hz, 2H), 7.90 (dd, J = 5.4, 3.0 Hz, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ  23.9, 55.0, 66.7, 119.1, 123.8, 131.3, 131.8, 134.4, 134.5, 167.5, 167.6. HRMS (ESI) 
calcd for C14H13NO4S (M+H)
+
: calcd 292.0565; obsd 292.0631. 
Pht-D-Cys[SCH2CH(OMe)2]-OAll (28). Cesium carbonate (252 mg, 0.772 mmol, 1.0 equiv.) 
was slowly added to a solution of 2-bromo-1,1-dimethoxyethane (35) (91.2 µL, 0.772 mmol, 1.0 
equiv.) and Pht-D-Cys-OAll (34) (225 mg, 0.772 mmol, 1.0 equiv.) in DMF (6 mL) at 40 ⁰C.  
This solution was stirred for 16 h at 40 ⁰C under N2.  The mixture was diluted with EtOAc (100 
mL) and washed with water (100 mL).  The aqueous layer was extracted a second time with 
EtOAc (100 mL) and the organic layers were combined, washed with brine (50 mL), filtered 
through MgSO4, concentrated, and the residue purified by flash chromatography eluting with 
5:13:1 hexanes-EtOAc to isolate 28 as a yellow oil (131 mg, 45%). Rf 0.50 (1:1 hexanes-
EtOAc). 
 1
H NMR (400 MHz, CDCl3) δ 2.64 (dd, J = 14.0, 5.0 Hz, 1H), 2.76 (dd, J = 14.0, 5.7 
Hz, 1H), 3.36 (s, 6H), 3.39 (dd, J = 14.3, 11.4 Hz, 1H), 3.54 (dd, J = 14.3, 4.4 Hz, 1H), 4.49 (t, J 
= 5.4 Hz, 1H), 4.67 (d, J = 5.5 Hz, 2H), 5.10 (dd, J = 11.4, 4.4 Hz, 1H), 5.23 (d,  J = 10.4 Hz, 
1H), 5.29 (d, J = 17.0 Hz, 1H), 5.80-5.92 (m, 1H), 7.75 (dd, J = 5.4, 3.1 Hz, 2H), 7.88 (dd, J = 
5.4, 3.1 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 31.3, 33.5, 51.3, 53.2, 53.8, 66.4, 104.8, 118.7, 
123.5, 131.3, 131.7, 134.2, 167.4, 167.8. HRMS (ESI) calcd for C18H21NNaO6S (M+Na)
+
: calcd 
402.0982; obsd 402.0987. 
2.7.3. First generation synthesis of tripeptide 39 (Scheme 2.8) 
Pht-Cys[SCH2CH(OMe)2]-Phe-Ala-NH2 (39). Morpholine (93.4 µL, 94.1 mg, 1.08 mmol, 3 
equiv.) was added to a solution of Pht-D-Cys(CH2CH(OMe)2)-OAll (28) (137 mg, 0.361 mmol, 
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1.0 equiv.) and Pd(PPh3)4 (42 mg, 0.036 mmol, 0.1 equiv.) in THF (15 mL).  This solution was 
stirred for 20 min under N2.  The mixture was diluted with EtOAc (50 mL) and washed with 5 % 
aq. citric acid (25 mL).  The aqueous layer was extracted a second time with EtOAc (25 mL) and 
the organic layers were combined, washed with brine (25 mL), filtered through MgSO4, 
concentrated, and the residue purified by flash chromatography eluting with 2:11:4 hexanes-
EtOAc to isolate free acid 37 as a colorless oil (89 mg, 72%).  
N-Hydroxysuccinimide (35.2 mg, 0.306 mmol, 1.0 equiv.) and N,N'-
dicyclohexylcarbodiimide (63.1 mg, 0.306 mmol, 1.0 equiv.) were added sequentially to a 
solution of Pht-Cys[CH2CH(OMe)2]-OH (37) (104 mg, 0.306 mmol, 1.0 equiv.) in CH2Cl2 (10 
mL) at 0 °C.  The solution was stirred for 20 min and then allowed to warm to rt and stirring was 
continued for 3 h under N2.  The mixture was filtered through a plug of cotton in a Pasteur 
pipette to remove the urea precipitate and the filtrate volume was reduced to 5 mL and placed in 
the freezer for 2 h.  The mixture was filtered again and the solution concentrated.  The residue 
was dissolved in DMF (5 mL) and L-phenylalanine (50.5 mg, 0.306 mmol, 1.0 equiv.) was 
added.  The solution was cooled to 0 °C and 
i
Pr2NEt (64.1 µL, 47.6 mg, 0.368 mmol, 1.2 equiv.) 
was added dropwise and the mixture left to stir for 18 h under N2.  The mixture was diluted with 
ethyl acetate (50 mL) and washed with water (50 mL), 10% aq. citric acid (50 mL) and brine (50 
mL). The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure.  
The residue, crude acid 38 (149 mg), was used immediately in the next reaction.      
Alaninamide hydrochloride (38 mg, 0.306 mmol, 1.0 equiv.) was added to a solution of 
dipeptide acid 38 (149 mg, 0.306 mmol, 1.0 equiv.) in CH2Cl2 (7 mL). The mixture was cooled 
to 0 °C and collidine (81.5 µL, 74 mg, 0.612 mmol, 2.0 equiv.) was added dropwise, followed by 
HATU (116.4 mg, 0.306 mmol, 1.0 equiv.).  The solution was allowed to warm to rt and stirred 
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under N2 for 16 h.  The mixture was concentrated and the residue purified by flash 
chromatography eluting with 4% CH3OH in CH2Cl2 to isolate a mixture which was further 
purified by HPLC eluting with a linear gradient of 25-65 % MeCN in H2O over 24 min, retention 
time 17.5-20.0 min.  This colorless solid 39 (115 mg, 68%) was composed of four compounds, 
all with the same molecular ion according to electrospray HRMS.  A portion was further 
purified, using the same HPLC conditions, collecting the major compound 39, RT 18 min. Rf 0.44 
(10% MeOH in CH2Cl2). 
1
H NMR (400 MHz, CDCl3) δ 1.37 (d, J = 7.2 Hz, 3H), 2.60 (dd, J = 
14.0, 5.0 Hz, 1H), 2.68 (dd, J = 14.0, 5.6 Hz, 1H), 3.02 (dd, J = 14.0, 6.2 Hz, 1H), 3.11 (dd, J = 
14.3, 10.4 Hz, 1H), 3.22 (dd, J = 14.0, 5.6 Hz, 1H), 3.32 (s, 3H), 3.33 (s, 3H), 3.48  (dd, J = 14.3, 
5.5 Hz, 1H), 4.44 (t, J = 5.3 Hz, 1H), 4.50 (t, J = 7.5 Hz, 1H), 4.56 (app. q, J = 6.0 Hz, 1H), 4.99 
(dd, J = 10.4, 5.5 Hz, 1H), 5.30 (br s, 1H), 6.41 (br s, 1H), 6.53 (d, J = 6.0 Hz, 1H), 6.59 (d, J = 
7.8 Hz, 1H), 6.97-7.05 (m, 5H), 7.79-7.90 (m, 4H).
 13
C NMR (125 MHz, CDCl3) δ 17.4, 29.9, 
31.6, 34.0, 37.4, 49.0, 52.4, 53.9, 54.3, 55.9, 104.8, 124.0, 127.5, 129.1, 129.4, 131.7, 134.7, 
136.1, 167.9, 169.1, 170.2, 174.4. HRMS (ESI) calcd for C27H32N4NaO7S (M+Na)
+
: calcd 
579.1884; obsd 579.1891. 
2.7.4. Second generation synthesis of tripeptide 39 (Scheme 2.9) 
Fmoc-Phe-Ala-NH2 (42). A solution of Fmoc-Phe-OH (40) (539 mg, 1.389 mmol, 1.0 equiv.) 
and HCl·H-Ala-NH2 (41) (173 mg, 1.389 mmol, 1.0 equiv.) in DMF (8 mL) was cooled to 0 °C.  
To this solution was added BOP reagent (614 mg, 1.389 mmol, 1.0 equiv.) followed by dropwise 
addition of 
i
Pr2EtN (960 µL, 713 mg, 5.560 mmol, 4.0 equiv.) and the solution was stirred under 
N2 for 16 h.  The reaction mixture was poured onto crushed ice (75 g) in a beaker and left to 
stand.  After 2 h, the precipitate was collected by vacuum filtration.  The dried solid was 
triturated with cold diethyl ether (25 mL x 2) and filtered to give 42 as a colorless solid (225 mg, 
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35%). Rf 0.16 (5% MeOH in CH2Cl2).
 1
H NMR (400 MHz, DMSO-d6) δ 1.22 (d, J = 7.0 Hz, 
3H), 2.76 (dd, J = 13.7, 10.9 Hz, 1H), 3.04 (dd, J = 13.7, 3.8 Hz, 1H), 4.10-4.17 (m, 3H), 4.19-
4.30 (m, 2H), 7.02 (br s, 1H), 7.17 (t, J = 7.1 Hz, 1H), 7.21-7.34 (m, 6H), 7.40 (td, J = 7.4, 1.8 
Hz, 2H), 7.60-7.65 (m, 3H), 7.87 (d, J = 7.5 Hz, 2H), 8.05 (d, J = 7.4 Hz, 1H).
 13
C NMR (125 
MHz, DMSO-d6) δ 18.4, 30.7, 35.7, 37.3, 46.5, 48.0, 56.1, 65.6, 120.0, 125.2, 125.3, 126.1, 
127.0, 127.5, 128.0, 129.2, 138.1, 140.6, 143.7 (2C), 155.7, 162.2, 170.9, 174.0. 
 
HRMS (ESI) 
calcd for C27H27N3NaO4 (M+Na)
+
: calcd 480.1894; obsd 480.1902.     
Pht-Cys[SCH2CH(OMe)2)]-Phe-Ala-NH2 (39). Diethylamine (6 mL, 50% v/v of total reaction 
mixture) was added to a suspension of Fmoc-Phe-Ala-NH2 (42) (148 mg, 0.323 mmol, 1.0 
equiv.) in MeCN (6 mL).  The mixture was stirred for 2 h under N2, concentrated, and purified 
by flash chromatography eluting with 1% 8% CH3OH in CH2Cl2 to isolate amine 43 as a 
colorless oil (68 mg, 89%).
 1
H NMR (400 MHz, CDCl3) δ 1.34 (d, J = 7.0 Hz, 3H), 2.71 (dd, J = 
13.6, 9.1 Hz, 1H), 3.17 (dd, J = 13.6, 3.9 Hz, 1H), 3.64 (dd, J = 8.7, 3.9 Hz, 1H), 4.47 (app p, J = 
7.0 Hz, 1H), 6.26 (br s, 1H), 6.86 (br s, 1H), 7.17-7.31 (m, 5H), 7.86 (d, J = 7.4 Hz, 1H).  
N-Hydroxysuccinimide (37 mg, 0.323 mmol, 1.0 equiv.) and by N,N'-
dicyclohexylcarbodiimide (67 mg, 0.323 mmol, 1.0 equiv.) were added sequentially to a solution 
of Pht-Cys(CH2CH(OMe)2)-OH (37) (110 mg, 0.323 mmol, 1.0 equiv.) in CH2Cl2 (10 mL) at 0 
°C.  The solution was stirred for 20 min and then allowed to warm to room to rt and stirring 
continued for 3 h under N2.  The mixture was filtered through a plug of cotton in a Pasteur 
pipette to remove the urea precipitate and the filtrate volume was reduced to 5 mL and placed in 
the freezer for 2 h.  The mixture was filtered again and the solution concentrated.  The residue 
was dissolved in DMF (5 mL) and to this solution was added dipeptide amine 43 (76 mg, 0.323 
mmol, 1.0 equiv.).  The solution was cooled to 0 °C and 
i
Pr2NEt (85 µL, 63 mg, 0.485 mmol, 1.5 
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equiv.) was added dropwise and left to stir for 18 h under N2.  The mixture was diluted with 
ethyl acetate (50 mL) and washed with water (50 mL), and brine (50 mL). The organic layer was 
dried over MgSO4, concentrated, and the residue purified by flash chromatography eluting with 4 
% CH3OH in CH2Cl2 to isolate a mixture of compounds of identical molecular weight as 
colorless solid 39 (115 mg, 65%).  The same HPLC method to that used in the first generation 
tripeptide synthesis (section 3.10) was used to isolate and purify the most abundant compound 
for characterization.  
1
H, 
13
C NMR, and mass spectrometry data were identical to 1
st
 generation 
tripeptide. 
2.7.5. Synthesis of thioenamide 49 and side products 50, 54, 55 (Scheme 2.13) 
Thioenamide (49) and Side Products. para-Toluenesulfonic acid (17 mg, 0.089 mmol, 1.0 
equiv.) was added to a solution of protected cysteine 28 (33 mg, 0.087 mmol, 1.0 equiv.) in 
benzene (33 mL), followed by addition of acetamide (26 mg, 0.435 mmol, 5.0 equiv.).  The 
solution was heated to reflux under N2.  After 4 h, the solution was concentrated under vacuum 
and the residue was purified by flash chromatography eluting with 4:13:11:1 hexanes-
EtOAc to isolate three products:   
Methyl Vinyl Ether (50) as a colorless oil (5 mg, 16%). Rf 0.52 (1:1 hexanes: EtOAc). 
1
H NMR 
(500 MHz, CDCl3) δ 3.29 (dd, J = 14.4, 4.2 Hz, 1H), 3.37 (dd, J = 14.4, 11.3 Hz, 1H), 3.54 (s, 
3H), 4.65 (d, J = 5.6 Hz, 2H), 5.05 (dd, J = 11.3, 4.2 Hz, 1H), 5.21 (d, J = 12.2 Hz, 1H), 5.22 (d, 
J = 10.4 Hz, 1H), 5.28 (d, J = 17.3 Hz, 1H), 5.81-5.91 (m, 1H), 6.72 (d, J = 12.2 Hz, 1H), 7.76 
(dd, J = 5.4, 3.1 Hz, 2H),  7.89 (dd, J = 5.4, 3.1, 2H); 
13
C NMR (125 MHz, CDCl3) δ 34.7, 51.4, 
56.8, 66.7, 92.1, 119.1, 123.8, 131.4, 132.0, 134.4, 157.5, 167.7, 168.3. HRMS (ESI) calcd for 
C17H18NO5S (M+H)
+
: calcd 348.0900; obsd 348.0931.  
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cis-Thioenamide (Z-49)  as a pale yellow oil (13 mg, 40%). Rf 0.25 (1:1 hexanes-EtOAc).
 1
H 
NMR (400 MHz, CDCl3) δ 2.10 (s, 3H), 3.41 (dd, J = 14.6, 4.3 Hz, 1H), 3.48 (dd, J = 14.6, 10.9 
Hz, 1H) 4.66 (d, J = 5.7 Hz, 2H), 4.99 (dd, J = 10.9, 4.3 Hz, 1H), 5.21 (d, J = 7.5 Hz, 1H), 5.24 
(d, J = 11.2 Hz, 1H), 5.27 (d, J = 17.2 Hz, 1H),  5.80-5.92 (m, 1H), 7.06 (dd, J = 11.1, 7.5 Hz, 
1H), 7.76-7.81 (m, 1H), 7.77 (dd, J = 5.3, 3.1 Hz, 2H), 7.79-7.85 (m, 1H), 7.88 (dd, J = 5.3, 3.1 
Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 23.3, 34.1, 52.9, 66.9, 99.4, 119.3, 123.8, 130.2, 131.3, 
131.7, 134.7, 167.5, 167.7, 167.9. HRMS (ESI) calcd for C18H19N2NO5S (M+H)
+
: calcd 
375.1009; obsd 375.0997. 
trans-Thioenamide (E-49) as a pale yellow oil (4 mg, 12%). Rf  0.12 (1:1 hexanes-EtOAc). 
1
H 
NMR (400 MHz, CDCl3) δ 1.98 (s, 3H), 3.40 (app. s, 1H), 3.42 (d, J = 2.5 Hz, 1H), 4.66 (d, J = 
5.7 Hz, 2H), 5.04 (dd, J = 9.1, 6.7 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 5.28 (dd, J = 17.2, 
1.3 Hz, 1H), 5.63 (d, J = 13.2 Hz, 1H), 5.80-5.92 (m, 1H), 7.04 (dd, J = 13.2, 10.8 Hz, 1H), 7.06-
7.13 (m, 1H), 7.75 (dd, J = 5.4, 3.0 Hz, 2H), 7.88 (dd, J = 5.4, 3.0 Hz, 2H); 
13
C NMR (125 MHz, 
CDCl3) δ 23.3, 29.8, 33.8, 51.7, 66.8, 102.5, 119.1, 123.9, 130.4, 131.4, 131.9, 134.4, 166.5, 
167.6, 168.0. HRMS (ESI) calcd for C18H19N2O5S (M+H)
+
: calcd 375.1009; obsd. 375.1010 
2:1 Adduct 54. para-Toluenesulfonic acid (18 mg, 0.092 mmol, 1.0 equiv.) was added to a 
solution of protected cysteine 28 (35 mg, 0.092 mmol, 1.0 equiv.) in benzene (26 mL), followed 
by addition of acetamide (5 mg, 0.092 mmol, 1.0 equiv.).  This solution was heated to reflux 
under N2.  After 4 h, the solution was concentrated under vacuum and the crude product was 
purified by flash chromatography eluting with 2:11:1 hexanes-EtOAc to isolate 54 as a pale 
yellow oil (26 mg, 81%). Rf 0.24 (1:1 hexanes-EtOAc).
 1
H NMR (400 MHz, CDCl3) δ 2.17 (s, 
1.5H), 2.18 (s, 1.5H), 3.34 (dd, J = 14.3, 4.0 Hz, 0.5H), 3.35 (dd, J = 14.3, 4.0 Hz, 0.5H), 3.48 
(dd, J = 10.9, 7.2 Hz, 1H), 3.51-3.61 (m, 2H), 4.62-4.64 (m, 2H), 4.65-4.70 (m, 2H), 4.86 (dd, J 
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= 10.9, 4.0 Hz, 0.5H), 4.92 (dd, J = 10.8, 4.1 Hz, 0.5H), 5.10 (dd, J = 10.0, 5.3 Hz, 1H), 5.18-
5.33 (m, 4H), 5.78-5.94 (m, 2H), 6.09 (d, J = 14.7 Hz, 0.5H), 6.10 (d, J = 14.7 Hz, 0.5H), 6.33 
(d, J = 14.7 Hz, 0.5H), 6.36 (d, J = 14.7 Hz, 0.5H), 7.09 (d, J = 11.3 Hz, 1H), 7.67-7.91 (m, 8H), 
8.26 (d, J = 11.3 Hz, 0.5H), 8.31 (d, J = 11.3 Hz, 0.5H); 
13
C NMR (100 MHz, CDCl3) δ 14.3, 
21.2, 23.3, 23.4, 32.4, 32.5, 32.7, 33.0, 51.8, 52.0, 53.5, 53.6, 60.5, 66.8, 66.9, 111.2, 111.4, 
119.1, 119.2, 119.3, 122.3, 122.5, 123.8 (2C), 124.0 (2C), 129.4, 129.5, 130.8, 131.0, 131.2, 
131.4, 131.6, 131.7, 131.9, 134.2, 134.3, 134.7, 167.2, 167.3, 167.4, 167.5, 167.7, 167.8, 167.9 
(2C). HRMS (ESI) calcd for C34H31N3O9S2 (M+H)
+
: calcd 690.1574; obsd 690.1584. 
Pyrrole 55. para-Toluenesulfonic acid (17 mg, 0.087 mmol, 1.0 equiv.) was added to a solution 
of protected cysteine 28 (33 mg, 0.087 mmol, 1.0 equiv.) in benzene (20 mL), followed by 
addition of acetamide (5 mg, 0.087 mmol, 1.0 equiv.).  The solution was heated to reflux under 
N2.  After 22 h, the solution was concentrated under vacuum and the crude product was purified 
by flash chromatography eluting with 2:11:1 hexanes-EtOAc to isolate 55 as a yellow oil (13 
mg, 38%). Rf 0.51 (1:1 hexanes-EtOAc).
 1
H NMR (400 MHz, CD3OD) δ 2.35 (s, 3H), 3.48 (dd, J 
= 14.8, 3.8 Hz, 1H), 3.67 (dd, J = 14.8, 11.3 Hz, 1H), 4.65 (dt, J = 5.7, 1.4 Hz, 2H), 5.10 (dd, J = 
11.3, 3.8 Hz, 1H), 5.20 (ddd, J = 10.5, 2.6, 1.5 Hz, 1H), 5.27 (ddd, J = 17.2, 3.1, 1.5 Hz, 1H), 
5.89 (ddt, 17.2, 10.5, 5.6 Hz, 1H), 6.25 (dd, J = 3.4, 1.7 Hz, 1H), 7.14 (dd, J = 3.4, 2.4 Hz, 1H), 
7.21 (dd, J = 2.2, 1.8 Hz, 1H), 7.82-7.84 (m, 4H); 
13
C NMR (100 MHz, CDCl3) δ 21.9, 34.2, 
54.0, 67.5,  117.3, 118.6, 118.9, 121.6, 123.4, 124.4, 132.7, 132.8, 135.7, 168.7, 168.8, 169.3. 
HRMS (ESI) calcd for C20H19N2O5S (M+H)
+
: calcd 399.1009; obsd 399.1017. 
Thioenamide 49 using BF3·OEt2. Acetamide (15 mg, 0.132 mmol, 5.0 equiv.) and boron 
trifluoride diethyl etherate (31 µL, 36 mg, 0.250 mmol, 5.0 equiv.) were added sequentially to a 
solution of cysteine 28 (19 mg, 0.050 mmol, 1.0 equiv.) in benzene (11 mL).  The solution was 
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heated to reflux under N2.  After 40 min, the solution was concentrated under vacuum and the 
residue subjected to flash chromatography eluting with 3:11:1 hexanes-EtOAc to isolate cis-
thioenamide Z-49 (9 mg, 47%) and trans-thioenamide E-49 (2 mg, 10%) as two pale yellow oils.  
See characterization above.  
Aldehyde 56. Trifluoroacetic acid (1 mL) at 0 °C was added slowly to a round bottomed flask 
charged with protected cysteine 28 (24 mg, 0.063 mmol, 1.0 equiv.) at 0 °C.  The solution was 
stirred under N2 in an ice bath.  After 1 h, the solution was concentrated  and subjected to flash 
chromatography, eluting with 3:1 hexanes-EtOAc to isolate 56 (20 mg, 95%). Rf 0.50 (1:1 
hexanes-EtOAc).
 1
H NMR (400 MHz, CDCl3) δ 3.20 (dd, J = 14.5, 2.4 Hz, 1H), 3.29-3.35 (m, 
3H), 4.66 (dd, J = 5.8, 0.9 Hz, 2H), 5.01 (dd, J = 9.6, 6.3Hz, 1H), 5.23 (dd, J = 10.4, 1.0 Hz, 1H), 
5.29 (dd, J = 17.2, 1.3 Hz, 1H), 5.81-5.92 (m, 1H), 7.77, (dd, J = 5.4, 3.1, 2H), 7.89 (dd, J = 5.4, 
3.0, 2H), 9.49 (dd, J = 4.1, 2.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 30.6, 40.6, 50.8, 66.9, 
119.2, 123.9, 131.2, 131.8, 134.5, 167.5, 167.5, 193.5.  
Thioenamide 49 using B(OH)3. Acetamide (4 mg, 0.075 mmol, 1.0 equiv.) and boric acid (23 
mg, 0.375 mmol, 1.0 equiv.) were added sequentially to a solution of cysteine aldehyde 56 (25 
mg, 0.075 mmol, 1.0 equiv.) in toluene (25 mL) under N2.  The solution was stirred and heated at 
reflux, with 1 equivalent of acetamide added daily until 
1
H NMR of the crude mixture showed 
consumption of aldehyde 56.  After 3 days, the total amount of acetamide added was 22 mg 
(0.375 mmol, 5.0 equiv.).   The solution was concentrated and the residue subjected to flash 
chromatography eluting with 3:11:1 hexanes-EtOAc to isolate cis-thioenamide Z-49 (16 mg, 
57%) and trans-thioenamide E-49 (2 mg, 7%), each as a pale yellow oil.  See characterization 
above. 
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2.8. NMR Spectra 
 
1
H NMR, Compound 32, CDCl3, 400 MHz 
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13
C NMR, Compound 32, CDCl3, 100 MHz 
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1
H NMR, Compound 33, CDCl3, 400 MHz 
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13
C NMR, Compound 33, CDCl3, 100 MHz  
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1
H NMR, Compound 34, CDCl3, 400 MHz 
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13
C NMR, Compound 34, CDCl3, 100 MHz 
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1
H NMR, Compound 28, CDCl3, 400 MHz 
 
53 
 
13
C NMR, Compound 28, CDCl3, 100 MHz 
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1
H NMR, Compound 39, CDCl3, 400 MHz 
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13
C NMR, Compound 39, CDCl3, 125 MHz 
56 
 
  
1
H NMR, Compound 42, DMSO-d6, 400 MHz 
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13
C NMR, Compound 42, DMSO-d6, 125 MHz 
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1
H NMR, Compound Z-49, CDCl3, 500 MHz 
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13
C NMR, Compound Z-49, CDCl3, 125 MHz 
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13
C NMR Compound E-49, CDCl3, 125 MHz 
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1
H NMR, Compound 50, CDCl3, 500 MHz 
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13
C NMR, Compound 50, CDCl3, 125 MHz 
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1
H NMR, Compound 54, CDCl3, 400 MHz 
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13
C NMR, Compound 54, CDCl3, 100 MHz 
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1
H NMR, Compound 55, CD3OD, 400 MHz 
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13
C NMR Compound 55, CDCl3, 100 MHz 
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1
H NMR, Compound 56, CDCl3, 400 MHz 
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13
C NMR, Compound 56, CDCl3, 100 MHz 
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2.9. Crystallographic data for lanthionine 36 
 
 
 
 
 
 
Lanthionine 36
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Chapter 3. Cysteine Epimerization and an Improved Synthesis of the Building 
Block in Enantioenriched Form 
 
3.1. A Strange Problem 
 As we moved from couplings of aldehyde 56 with acetamide to reactions involving 
amino amide coupling partners, we noticed a recurring theme in the thioenamide products.  The 
NMR spectra always displayed multiple species of the desired product.  Though epimerization 
issues are always under consideration in peptide chemistry, we were aware that restricted 
conformations, especially with an unprecedented functional group with hydrogen bonding 
capacity, could also explain the presence of multiple species on the timescale of 
1
H NMR 
experiments.  Given the scarcity of thioenamide-containing compounds in the literature, we 
proceeded with our optimization of amino amide thioenamide formation, always carefully 
bearing in mind this strange problem.   
Thioenamide 62 (see Chapter 4 for more detail of this reaction) was the first compound to 
yield two sets of sharp, distinguishable thioenamide 
1
H NMR signals that definitively revealed a 
1:1 ratio of the two species (Figure 3.1).  The thioenamide olefin protons adjacent to the amide 
nitrogen clearly showed a cis relationship (J = 7.4 Hz) about the double bond in both species.  
The minor trans thioenamide isomer (J = 13.8 Hz) was removed via column chromatography 
prior to this analysis.  The curious 1:1 mixture gave us pause, as both conformational bias and 
epimerization would be expected to produce a degree of isomerization, rather than a perfect 
equimolar mixture.  This pivotal result encouraged us to review previous reactions involving our 
cysteine building block and strongly consider the possibility of racemization.   
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Figure 3.1. Formation of thioenamide 62 and 1H NMR (CDCl3, 400 MHz, 6.75-7.00 ppm 
region) evidence for two sets of cis thioenamide protons (H shown in red on 62) 
 
3.2. Imidazolidinone: Evidence for Epimerization  
When cysteine-derived acetal 28 was reacted with alaninamide 63, instead of  
thioenamide 65, we obtained imidazolidinone 64 (Scheme 3.1).  For further details of this 
reaction, see Chapter 4.  With the generation of a new stereocenter, imidazolidinone 64 is 
predicted to be a mixture of diastereomers about the newly formed stereocenter (Scheme 3.1, 
compound 64, center b).  Two species could be separated via flash chromatography.  However, 
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characterization using NMR revealed that each specimen was, itself, a mixture of two 
compounds.  This observation was consistent with a scrambled stereocenter at Cα in cysteine 28 
resulting in a more complicated mixture of compound 64 than anticipated, i.e. epimers at both a 
and b (Scheme 3.1).  This result demonstrated that it was not specifically the thioenamide 
functional group that was responsible for the mixture of apparently isomeric compounds.  
 
Scheme 3.1. Formation of imidazolidinone 64 
3.3. The Canary in the Coal Mine 
An even earlier indication that there was something awry in the synthesis of  our cysteine 
building block was the observation that tripeptide 39 (see Chapter 2, Scheme 2.8) was obtained 
as a mixture of at least three compounds, inseparable by flash chromatography.  In this context, 
the mixture could arise from a racemic cysteine 28, in combination with epimerization taking 
place at the phenylalanine α-carbon during peptide coupling (Figure 3.2, A).  Indeed, when the 
order of events for tripeptide formation was changed, so that epimerization of phenylalanine was 
less likely (see Chapter 2, Scheme 2.9), the product mixture was simplified to two compounds 
with the same molecular mass (Figure 3.2, B).  This early result showed, in retrospect, that the 
issue of isomeric species could be traced back to our original cysteine building block.  
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Figure 3.2. HPLC Chromatograms of tripeptide 39. (A) Synthesized according to Scheme 2.8 
(first generation) and (B) Synthesized according to Scheme 2.9 (second generation) Column- 
Altima 10 µm, C18 (250 mm × 10 mm) 
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3.4. The Usual Suspects  
The most obvious culprit, in terms of a reaction with the potential to be accompanied by 
racemization, was the thiol alkylation (Scheme 3.2, step V).  Alkaline conditions, coupled with 
the strong electron-withdrawing nature of the phthalimido group, prime this step for elimination 
of the thiolate anion.  Racemization could arise after protonation of a dehydroalanine (Scheme 
3.3).  Additionally, the previous isolation of dimeric thioether 36 illuminated the high potential 
for elimination and conjugate addition. 
 
Scheme 3.2. 1st Generation route to cysteine 28 (reprised scheme 2.6) 
 
Scheme 3.3. Proposed mechanism for racemization and dimer formation during 1st generation 
alkylation 
 
Epimerization of cysteine is a well-documented issue.
1-5 
 A proven approach to 
minimizing elimination during alkylation of cysteine thiols is to use mild, buffered, phase-
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transfer conditions.
6
  Thus, Zha and Schmidt reported the formation of lanthionine 68 via 
alkylation of cysteine 67 (Scheme 3.4). 
 
Scheme 3.4. Schmidt's racemization-free lanthionine formation 
To compensate for the strong electron-withdrawing nature of the phthalimido protecting 
group, we took a step backwards and attempted alkylation of Fmoc-protected cysteine 69 
(Scheme 3.5).  Disappointingly, the desired thioether 70 was not observed. 
 
Scheme 3.5. Phase transfer conditions applied to Fmoc-D-Cys(H)-OAll (69) 
A host of alterations to the reaction conditions including changes in temperature, equivalents of 
electrophile, solvent, pH, and concentration all failed to produce any of the desired compound.  
These reactions regularly yielded a mixture of starting material thiol and the corresponding 
disulfide 71.   
When the pH was raised to >10, using NaOH, S-fluorenylmethyl adduct 73 was isolated 
in 18% yield (Scheme 3.6).  This arises from β-elimination of dibenzofulvene and subsequent 
addition of unreacted thiol 69 across the double bond.  The fact that these reactions failed to 
produce desired product 70 (Scheme 3.5), even in the presence of excess 2-bromo-1,1-dimethoxy 
acetal, but could generate fluorenylmethyl thioether 73, albeit in low yield, was a crucial result.  
This indicated that 2-bromo-1,1-dimethoxyethane was not a capable electrophile for our 
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transformation and urged us to find an alternative approach.  The more reactive 2-iodo-1,1-
dimethoxyethane was not commercially available, and attempts to generate it from 2-bromo-1,1-
dimethoxyethane were unsuccessful.   
 
Scheme 3.6. Mechanism of formation of S-fluorenylmethyl adduct 73 
3.5. A New Electrophile 
  The original synthesis of aldehyde 56 required hydrolysis of the acetal functionality in 
compound 28.  We envisioned an alternative approach towards aldehyde 56 involving oxidation 
from alcohol 74 (Scheme 3.7). 
 
Scheme 3.7. Generation of aldehyde 56 
Using 2-iodoethanol, we were able to increase the yield of our alkylation to 97% with gentle 
heating (Scheme 3.8).  Alkylation was followed by typical conditions for Fmoc removal and 
reprotection of the α-amine as the phthalimide.  Oxidation of the primary alcohol using Dess-
Martin periodane proceeded smoothly to yield aldehyde 56, setting the stage for thioenamide 
formation.  Notwithstanding these new, mild reaction conditions for alkylation, the thioenamide 
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product 62, generated via our new alkylation conditions, still yielded a mixture of two 
compounds; though now in a 1.0:0.7 ratio (Figure 3.3). 
 
Scheme 3.8. Improved alkylation and oxidation to aldehyde 56 
 
Figure 3.3. 1H NMR of thioenamide 62 synthesized via Scheme 3.8 invoking the phase transfer 
alkylation (1H NMR, CDCl3, 400 MHz) 
 
3.6. Epimerization during Thioenamide Formation 
 The small change in the ratio of signals in the proton NMR suggested that our hypothesis 
of racemization was correct, but involved more than one step in the sequence contributing to the 
erosion of stereochemistry at Cα.  The most disconcerting prospect was that one of those 
reactions was thioenamide formation, the step that we spent a great deal of time optimizing, and 
D L 
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for which there is no literature precedent.  To determine this possibility, we investigated the 
stereochemistry of our starting material, alcohol 74, and then reacted under our Lewis acid 
promoted thioenamide formation. 
 Investigation began with examination of cysteine alcohol 74 (Scheme 3.8) via chiral 
HPLC (Figure 3.4). This analysis revealed that isomerization had already taken place.   
Separation of the two enantiomers by chiral HPLC afforded us the opportunity to measure their 
optical rotations.  The values, [α]D
25 = +59.8 (c 0.5, CHCl3) and -62.9 (c 0.5, CHCl3), served as 
further confirmation that their relationship was enantiomeric.  While the near 54% to 46% ratio 
of isomers pointed strongly to previous reactions being problematic, we also needed to determine 
the level of epimerization during our thioenamide-forming reaction. 
Oxidation of the (+)-enantiomer was followed by thioenamide formation, again using 
Tcp-Val-NH2 (61), to form thioenamide 62.  The 
1
H NMR spectrum of the crude product showed 
a single diastereomer (Figure 3.5)!  This happy result reassured us that thioenamide generation 
can be achieved without damage to the diastereomeric ratio.   
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Figure 3.4. Chiral HPLC separation of enantiomers of phthalimido-protected cysteine 74; 
(Chiralcel OD-H [cellulose tris(3,5-dimethylphenylcarbamate] column from Daicel; 4.6 x 25 mm 
Method-Isocratic 20% isopropanol 80% n-hexane, 1 mL min-1, detection at 254 nm), optical 
rotations measured in chloroform at 25 °C 
 
 
Figure 3.5. Thioenamide generated from pure (+) enantiomer (1H NMR, CDCl3, 400 MHz) 
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3.7. The Epimerization Strikes Back 
 Clearly, the alkylation reaction conditions were only partially to blame for racemization.  
Epimerization was occurring elsewhere in the synthesis of our building block, perhaps in 
multiple steps.  We took a step backwards in our synthetic route to phthalimide 74 and 
investigated the stereochemical integrity of Fmoc-protected cysteine 75.  First, using chiral 
HPLC we investigated Fmoc-proteced cysteine 75 (Figure 3.6).  While the peak was broad, there 
appeared to be only a single isomer. 
 
Figure 3.6. Chiral HPLC trace of Fmoc-D-Cys(ethanol)-OAll (75) 
 Mosher derivatives can be used to determine the enantiomeric purity of a compound by 
measuring the ratio of the diastereomeric adducts.
7,8 
 Accordingly, we generated Mosher amide 
76 after Fmoc removal from 75 (Scheme 3.9).   
 
Scheme 3.9. Mosher's amide synthesis 
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This analysis allowed us to determine the degree of epimerization resulting from our amine 
deprotection and confirm that of all reactions preceding it.  Derivative 76 contains a 
trifluoromethyl group and can therefore be analyzed by 
19
F NMR.  The fluorine atoms of 
different diastereomers should have distinct chemical shifts enabling us to measure the ratio of 
original isomers.  With this approach, we observed 4-5% of the minor diastereomer of Mosher 
derivative 76 (Figure 3.7).   
 
Figure 3.7. 
19
F NMR (CDCl3, 376 MHz) of Mosher’s amide 76 
To corroborate this result we also performed chiral HPLC of Mosher’s amide 76 (Figure 3.8).  
This showed that the product was no more that 5% epimerized at this stage in the synthesis.  The 
degree of epimerization, determined by two different methods, was in good agreement. 
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Figure 3.8. Chiral HPLC chromatogram of Mosher’s Amide 76 
3.8. Return of the Phthalimido  
 At this juncture, all evidence pointed to conditions employed for the formation of the 
phthalimide being responsible for substantial epimerization of our cysteine α-carbon.  This 
transformation had always been performed with two equivalents of triethylamine at high 
temperature (Scheme 3.10).  Reducing the equivalents of base, and using a less basic reagent 
(pyridine) were ineffective at reducing the degree of epimerization.  Catalytic base (triethylamine 
or disoproylethylamine) led to very little desired product.  Even weak bases, such as pyridine, 
still scrambled the stereocenter to the same degree.  Lowering the temperature of the reaction 
was also an ineffective strategy.  
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Scheme 3.10. Fmoc removal and phthalimido protection 
Experimentation with phthalimide sources other than phthalic anhydride eventually led us 
to a report by Casimir et al. using methyl 2-[(succinimidooxy)carbonyl]benzoate (MSB, 79) to 
install the amine protecting group (Scheme 3.11).
9
  Casimir reported racemization-free synthesis 
of a small range of amino acids and peptides, but not cysteine itself. 
 
Scheme 3.11. Casimir's phthalimido protection method 
 Initial attempts to exchange the Fmoc protection for the phthalimido group using the 
conditions of Casimir with MSB were disappointing, resulting in degradation of material and no 
desired product (Scheme 3.12). 
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Scheme 3.12. Failed attempt at phthalimido protection 
 Many of the examples reported by Casimir were performed on free amino acids, rather 
than esters.  We hypothesized that the acid functionality facilitates the coupling of the amine by 
first forming the mixed anhydride (Scheme 3.13).  The anhydride is then set up to undergo 
intramolecular amide formation and subsequent 5-exo-trig cyclization to generate the imide. 
 
Scheme 3.13. Proposed mixed anhydride mechanism for phthalimido formation 
 To test our mixed anhydride hypothesis, we subjected S-trityl-cysteine 81 to Casimir’s 
conditions (Scheme 3.14).  The transformation proceeded smoothly with a yield of 84%.  While 
this was good news, it necessitated alteration of the order of events to generate enantioenriched 
alcohol 74.  The yield of the allyl ester formation remained high, but the alkylation step dropped 
to 75%.  Chiral HPLC was used to determine the purity of alcohol 74 produced via this route.  
The product contained only 6-15% of the undesired enantiomer via this improved route (Figure 
3.9, c.f. Figure 3.1 for racemic mixture).  Reactions I-III have been performed on multiple gram 
scale, while the alkylation (step IV) has been done with 800 mg with little-to-no drop in yield for 
any step.  This scale and level of epimerization was considered within acceptable range to 
continue on with our material towards synthesis of the C-terminal ring cypemycin. 
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Scheme 3.14. Improved route to alcohol 74 
 
Figure 3.9. Chiral HPLC of alcohol (+)-74 (Chiracel OD-H) Column-Chiracel OD-H, 1 mL min-
1, detection at 254 nm (4.6 mm x 250 mm) 
 
 
3.9. Experimental Procedures 
3.9.1. General Methods As is 2.7.1 
3.9.2. Synthesis of tetrachlorophthalimide-protected valinamide 61 and thioenamide 62 
(Scheme 3.1) 
Tcp-L-Val-NH2 (61). Tetrachlorophthalic anhydride (2.257 g, 7.89 mmol, 1.0 equiv.) and 
triethylamine (2.5 mL, 1.82 g, 17.94 mmol, 2.3 equiv.) were added to a solution of valinamide 
A
U
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
Minutes
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
92% 
8% 
Isocratic- 
20% 
i
PrOH/80%  n-hexane 
 
94 
 
hydrochloride (1.205 g, 7.89 mmol, 1.0 equiv.) in toluene (85 mL).  The mixture was heated at 
reflux under Dean-Stark conditions for 16 h.  The mixture was diluted with EtOAc (200 mL) and 
washed with a 5% aqueous citric acid solution (200 mL).  The aqueous layer was extracted a 
second time with EtOAc (50 mL) and the organic layers combined, washed with brine (50 mL), 
filtered through MgSO4, and concentrated.  The residue was subjected to flash chromatography, 
eluting with 3:1 hexanes-EtOAc to isolate 61 as a colorless solid (2.294 g, 76%). Rf 0.23 (2:1 
hexanes-EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 0.88 (d, J = 6.7 Hz, 3H), 1.14 (d, J = 6.6 Hz, 
3H), 2.77-2.88 (m, 1H),  4.39 (d, J = 11.2 Hz, 1H), 5.82 (br s, 1H), 6.60 (br s, 1H); 
13
C NMR 
(125 MHz, CDCl3) δ 19.6, 20.0, 27.4, 63.3, 127.0, 130.3, 140.9, 163.8, 170.1. HRMS (ESI) calcd 
for C13H10Cl4N2O3 (M+H)
+
: calcd 382.9518; obsd 382.9524.  
Mixture of diastereomers of thioenamide dipeptide 62. Boric acid (29 mg, 0.465 mmol, 5.0 
equiv.) and Tcp-Val-NH2 (61) (36 mg, 0.093 mmol, 1.0 equiv.) were added to a solution of 56 
(31 mg, 0.093 mmol, 1.0 equiv.) in xylenes (31 mL).  This mixture was brought to reflux and 
stirred for 24 h under N2.  Additional Tcp-Val-NH2 61 (13 mg, 0.4 equiv.) was added and reflux 
continued for an additional 16 h.  The mixture was concentrated and the crude residue was 
subjected to flash chromatography, eluting with 5:1->4:1 hexanes-EtOAc to isolate Z-62 [46 mg, 
71%; Rf 0.41 (2:1 hexanes-EtOAc)] and E-62 [(4 mg, 6% Rf 0.37 (2:1 hexanes-EtOAc)], each as 
a yellow solid. Data for Z-62 as a 1:1 mixture of diastereomers about the C-α of cysteine. 
1
H 
NMR (400 MHz, CDCl3) δ 0.88 (d, J = 6.6 Hz, 1.5H), 0.89* (d, J = 6.7 Hz, 1.5H), 1.08 (d, J = 
6.6 Hz, 1.5H), 1.13* (d, J = 6.6 Hz, 1.5H) 2.83 (dq, J = 11.1, 6.6 Hz, 0.5H), 2.94* (dq, J = 10.7, 
6.7 Hz, 0.5H), 3.40 (dd, J = 14.8, 3.7 Hz, 0.5H), 3.42* (dd, J = 14.6, 4.2 Hz, 0.5H), 3.50* (dd, J 
= 14.6, 10.8 Hz, 0.5H), 3.56 (dd, J = 14.8, 11.4 Hz, 0.5H), 4.48* (d, J = 10.7 Hz, 0.5H), 4.49 (d, 
J = 11.1 Hz, 0.5H) 4.60-4.77 (m, 2H), 4.91 (dd, J = 11.4, 3.7 Hz, 0.5H), 4.98* (dd, J = 10.7, 4.0 
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Hz, 0.5H), 5.19-5.36 (m, 3H), 5.77-5.97 (m, 1H), 6.78 (dd, J = 10.7, 7.4 Hz, 0.5H), 6.87* (dd, J 
= 10.8, 7.4 Hz, 0.5H), 7.72-7.76 (m, 3H), 7.72-7.94 (m, 4H); 
13
C NMR (125 MHz, CDCl3) δ 
19.5*, 19.8, 19.9, 20.4*, 27.0*, 27.5, 29.9*, 32.9, 33.2*, 53.1*, 53.5, 62.*, 63.5, 66.9, 66.9*, 
102.5*, 102.8, 119.2, 119.3*, 123.8, 124.0*, 127.3*, 127.5, 128.0*, 128.5, 130.21, 131.3*, 131.5, 
131.7, 134.6, 140.7, 163.7*, 164.2, 164.9, 165.4, 167.5, 167.5, 167.7*, 167.9. HRMS (ESI) calcd 
for C29H23Cl4N3O7S (M+H)
+
: calcd 698.0084; obsd 698.0079    
*NMR signals from undesired diastereomer resulting from L-cysteine 
3.9.3. Synthesis of imidazolidinone 64 (Scheme 3.1) 
Imidazolidinone 64. para-Toluenesulfonic acid (42 mg, 0.219 mmol, 1.0 equiv.) and Fmoc-L-
Ala-NH2 (68 mg, 0.219 mmol, 1.0 equiv.) were added to a solution of 28 (83 mg, 0.219, 1.0 
equiv.) in benzene (50 mL).  This solution was brought to reflux and stirred under N2 for 16 h.  
The mixture was concentrated and the residue subjected to flash chromatography, eluting with 
2:1->1:1 hexanes-EtOAc to isolate 64 as a yellow solid (52 mg, 67%). Rf 0.40 (1:2 hexanes-
EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 1.13 (app t, J = 8.2 Hz, 2H), 1.33 (br s, 1H), 2.03-2.14 
(m, 0.5H), 2.40-2.58(m, 1H), 2.69 (dd, J = 13.5, 7.1 Hz, 0.5H), 2.84-3.56 (m, 4H), 3.81 (br s, 
0.7H), 4.06 (br s, 0.3H), 4.24 (app t, 5.1 Hz, 1H), 4.50-5.24 (m, 5H), 5.21 (d, J = 10.4 Hz, 1H), 
5.27 (dd, J = 17.2, 1.3 Hz, 1H), 5.84 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 6.78-7.08 (m, 1H), 7.32 (t, 
J = 7.2 Hz, 2H) 7.30-7.44 (m, 2H), 7.52-7.57 (m, 2H), 7.73-7.77 (m, 4H), 7.84-7.90 (m, 2H); 
13
C 
NMR* (125 MHz, CDCl3) δ 17.5, 17.7, 18.0, 18.1, 31.3, 32.6, 37.2, 38.2, 47.3, 51.2, 52.1, 54.8, 
66.9, 68.5, 69.1, 119.3, 120.2, 123.9 (2C), 124.6, 124.8, 127.3, 128.0, 131.3, 131.7, 134.6, 141.5, 
143.7, 154.1, 167.6, 167.7, 173.4. HRMS (ESI) calcd for C34H32N3O7S (M+H)
+
: calcd 626.1955; 
obsd 626.1961 
*Contains diastereomers, often indistinguishable from one another 
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3.9.4. First phase transfer alkylation of cysteine (Scheme 3.8) 
Fmoc-D-Cys[S(CH2CH2OH)]-OAll (75). Trifluoroacetic acid (0.675 mL, 1.005 g, 8.813 mmol, 
5.0 equiv.) and triethylsilane (1.408 mL, 1.025 g, 8.813 mmol, 5.0 equiv.) were added to a 
solution of 32 (1.103 g, 1.763 mmol, 1.0 equiv.) in DCM (10 mL) at 0 °C.  After 5 min, the 
solution was allowed to warm to rt over 1 h.  The mixture was concentrated and subjected to 
flash chromatography, eluting in 5:1 hexanes-EtOAc to isolate free thiol 69 (525 mg, 78%). Rf 
0.34 (3:1 hexanes-EtOAc). 
2-Iodoethanol (214 µL, 471 mg, 2.74 mmol, 2.0 equiv.) followed by aqueous 0.5 M 
NaHCO3 (34 mL) was added to a solution of thiol 69 in EtOAc (34 mL).  To this biphasic 
mixture was added tetrabutylammonium hydrogen sulfate (2.3 g, 6.85 mmol, 5.0 equiv.) and the 
mixture was vigorously stirred for 16 h at rt.  The mixture was diluted with EtOAc (100 mL) and 
washed with saturated NaHCO3 (75 mL).  The aqueous layer was extracted a second time with 
EtOAc (50 mL) and the organic layers were combined, washed with brine (50 mL), filtered 
through MgSO4, concentrated, and the residue purified by flash chromatography eluting with 
3:11:1 hexanes-EtOAc to isolate alcohol 75 as a colorless solid (568 mg, 97%). Rf 0.34 (1:1 
hexanes-EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 2.37 (br s, 1H), 2.72 (dd, J = 14.2, 6.0 Hz, 1H), 
2.77 (dd, J = 14.2, 5.7 Hz, 1H), 3.01 (dd, J = 14.5, 5.6 Hz, 1H), 3.04 (dd, J = 14.5, 5.2 Hz, 1H), 
3.68-3.77 (m, 2H), 4.24 (t, J = 7.0 Hz, 1H), 4.37-4.46 (m, 2H), 4.60-4.72  
(m, 3H), 5.28 (d, J = 10.4 Hz, 1H), 5.36 (d, J = 17.2 Hz, 1H), 5.81 (d, J = 8.0 Hz, 1H), 5.88-5.95 
(m, 1H), 7.32 (t, J = 7.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.61 (d, J = 5.0 Hz, 2H), 7.77 (d, J = 
7.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 35.0, 36.4, 47.2, 54.2, 61.0, 64.6, 66.6, 67.3, 119.5, 
120.1, 125.2, 127.2, 127.9, 131.4, 141.4, 143.8, 143.9, 155.5, 156.0, 170.5. HRMS (ESI) calcd 
for C23H26NO5S (M+H)
+
: calcd 428.1526; obsd. 428.1543 
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3.9.5. Synthesis of Mosher’s amide 76 (Scheme 3.9) 
 (S)-Methoxy(trifluoromethyl)phenylacetyl-D-Cys[S(CH2CH2OH)]-OAll 76.  Diethylamine 
(2 mL, 50% v/v) was added to a solution of Fmoc-D-Cys(ethanol)-OAll 75 (39 mg, 0.0912 
mmol, 1.0 equiv.) in MeCN (2 mL) and the mixture was stirred under N2 for 1.5 h.  The mixture 
was concentrated and the crude residue was taken directly into the next step.   
(S)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoic acid (21 mg, 0.0912 mmol, 1.0 equiv.) 
was dissolved in DMF (0.5 mL) and to this solution was added EDC (14 mg, 0.091 mmol, 1.0 
equiv.) and HOBt (14 mg, 0.091 mmol, 1.0 equiv.) sequentially.  This mixture was allowed to 
stir under N2 for 25 min at rt.   
The crude, free amine mixture was dissolved in DMF (0.5 mL) and this solution was 
added dropwise to the solution  of activated Mosher’s acid.  The mixture was stirred under N2 for 
16 h.  The mixture was diluted with EtOAc (75 mL) and washed with H2O (75 mL).  The 
aqueous layer was extracted a second time with EtOAc (50 mL).  The organic layers were 
combined, washed with brine (50 mL), filtered through MgSO4, concentrated, and the residue 
purified by flash chromatography eluting with 4:1 hexanes-EtOAc to isolate Mosher’s amide 76 
as a colorless oil (12 mg, 32%). Rf 0.32 (1:1 hexanes-EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 
2.28 (br s, 1H), 2.72-2.82 (m, 2H), 3.06 (dd, J = 14.1, 6.1 Hz, 1H), 3.11 (dd, J = 14.1, 4.9 Hz, 
1H), 3.42 (d, 
5
JHF = 1.3 Hz, 3H), 3.73 (dd, J = 11.5, 6.3 Hz, 1H), 3.78 (dd, J = 11.5, 6.0 Hz, 1H), 
4.64 (ddt, J =  13.0, 5.9, 1.3 Hz, 1H), 4.69 (ddt, J = 13.0, 5.9, 1.3 Hz, 1H), 4.90 (ddd, J = 8.1, 
6.0, 5.0 Hz, 1H), 5.29 (dd, J = 10.5, 1.3 Hz, 1H), 5.35 (dd, J = 17.2, 1.3 Hz, 1H), 5.86-5.95 (m, 
1H), 7.40-7.42 (m, 3H), 7.54-7.57 (m, 2H), 7.76 (d, J = 8.0 Hz, 1H);
 13
C NMR (125 MHz, 
CDCl3) δ 34.3, 36.2, 52.5, 55.2, 61.0, 66.7, 119.6, 127.7, 128.7, 128.8, 129.8, 131.3, 132.0, 
166.7, 169.9. 
19
F NMR (376 MHz, CDCl3, unreferenced) δ -68.81 (0.06H), -68.90 (0.94H) 
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3.9.6. Enantioenriched synthesis of cysteine alcohol 74 and oxidation to 56 (Scheme 3.14) 
Pht-D-Cys(Trt)-OH (82). To a stirred suspension of H-D-Cys(Trt)-OH (81) (632 mg, 1.739 
mmol, 1.0 equiv.) and Na2CO3 (737 mg, 6.956 mmol, 4.0 equiv.) in H2O (10 mL) was added 
MeCN (16 mL) and methyl 2-((Succinimidooxy)carbonyl)benzoate (MSB)
9
 (482 mg, 1.739 
mmol, 1.0 equiv.).  The mixture was allowed to stir for 16 h.  The mixture was diluted with 
EtOAc (150 mL) and washed with 1M aq. HCl (150 mL).  The aqueous layer was extracted a 
second time with EtOAc (50 mL).  The organic layers were combined, washed with brine (50 
mL), filtered through MgSO4, concentrated, and the residue purified by flash chromatography 
eluting with 2% methanol in DCM to isolate acid 82 as a colorless solid (746 mg, 86%). Rf 0.30 
(streaky) (9:1 CH2Cl2:MeOH). 
1
H NMR (500 MHz, CDCl3) δ 2.96 (dd, J = 13.8, 4.5 Hz, 1H), 
3.41 (dd, J = 13.8, 11.2 Hz, 1H), 4.34 (dd, J = 11.2, 4.5 Hz, 1H), 7.17-7.31 (m, 10H), 7.35-7.38 
(m, 5H), 7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.81 (dd, J = 5.5, 3.0 Hz, 2H);
13
C NMR (125 MHz, 
CDCl3) δ 30.7, 51.6, 67.7, 123.8, 127.0, 128.2, 129.8, 131.9, 134.3, 144.4, 167.3, 173.2. HRMS 
(ESI -ve ion) calcd for C30H23NO4S (M-H): calcd 492.1275; obsd 492.1277         
Pht-D-Cys(Trt)-OAll (33). Allyl bromide (73 µL, 102 mg, 0.847 mmol, 1.1 equiv.) and Cs2CO3 
(125 mg, 0.385 mmol, 0.5 equiv.) were added to a solution of Pht-D-Cys(Trt)-OH (82) (380 mg, 
0.770 mmol, 1.0 equiv.) in DMF (3 mL).  The mixture was stirred overnight at rt under N2.  The 
mixture was diluted with EtOAc (150 mL) and washed with water (75 mL).  The aqueous layer 
was extracted a second time with EtOAc (75 mL).  The organic layers were combined, washed 
with brine (50 mL), filtered through MgSO4, and concentrated.  The residue was subjected to 
flash chromatography, eluting with 5:1 hexanes-EtOAc to isolate 33 as a colorless solid (358 mg, 
87%). Characterization identical for racemic (±)-33. 
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Pht-D-Cys[S(CH2CH2OH)]-OAll [(+)-74]. 2-Iodoethanol (163 µL, 360 mg,  2.094 mmol, 2.0 
equiv.) and aqueous 0.5 M NaHCO3 (26 mL) were added to a solution of thiol 34 (305 mg, 1.047 
mmol, 1.0 equiv.) in EtOAc (26 mL).  To this biphasic mixture was added tetrabutylammonium 
hydrogen sulfate (1.78 g, 5.235 mmol, 5.0 equiv.) and the mixture was vigorously stirred for 16 h 
at rt under N2.  The mixture was diluted with EtOAc (100 mL) and washed with saturated 
NaHCO3 (75 mL).  The aqueous layer was extracted a second time with EtOAc (50 mL) and the 
organic layers were combined, washed with brine (50 mL), filtered through MgSO4, 
concentrated, and the residue purified by flash chromatography eluting with 4:11:1 hexanes-
EtOAc to isolate alcohol (+)-74 as a colorless solid (262 mg, 75%). Rf 0.46 (2:1 EtOAc-hexanes) 
1
H NMR (400 MHz, CDCl3) δ 2.46 (br s, 1H), 2.68 (ddd, J = 13.8, 6.5, 5.6 Hz, 1H), 2.81 (dt, J = 
13.8, 5.6 Hz, 1H), 3.38 (dd, J = 14.4, 11.1 Hz, 1H), 3.44 (dd, J = 14.4, 5.0 Hz, 1H), 3.71-3.80 
(m, 2H), 4.66 (d, J = 1.3 Hz, 1H), 4.67 (d, J = 1.3 Hz, 1H) 5.07 (dd, J = 11.1, 5.0 Hz, 1H), 5.23 
(dd, J = 10.5, 1.2 Hz, 1H), 5.29 (dd, J = 17.2, 1.4 Hz, 1H), 5.82-5.91 (m, 1H), 7.78 (dd, J = 5.5, 
3.1 Hz, 2H), 7.89 (dd, J = 5.5, 3.1 Hz, 2H); 
 13
C NMR (125 MHz, CDCl3) δ 31.2, 35.3, 51.7, 
60.9, 66.7, 119.0, 123.7, 131.2, 131.6, 164.5, 155.6, 167.6, 167.8. HRMS (ESI) calcd for 
C16H18NO5S (M+H)
+
: calcd 336.0900; obsd 336.0909. 
Aldehyde (56). Dess-Martin periodane (61 mg, 0.144 mmol, 2.0 equiv.) was added to a solution 
of alcohol 74 (24 mg, 0.072 mmol, 1.0 equiv.) in DCM (1 mL).  This mixture was allowed to stir 
under N2 for 4 h.  The mixture was concentrated and subjected to flash chromatography, eluting 
with 4:1 hexanes-EtOAc to isolate 56 as a colorless oil (20 mg, 84%).  Characterization 
identical for racemic 56. 
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 3.10. NMR Spectra 
 
1
H NMR, Compound 61, CDCl3, 500 MHz 
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13
C NMR, Compound 61, CDCl3, 125 MHz 
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1
H NMR, Compound Z-62 as a mixture of diastereomers, CDCl3, 500 MHz 
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13
C NMR, Compound Z-62 as a mixture of diastereomers, CDCl3, 125 MHz 
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1
H NMR, Compound 64, CDCl3, 500 MHz 
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13
C NMR, Compound 64, CDCl3, 125 MHz 
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1
H NMR, Compound 75, CDCl3, 500 MHz 
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13
C NMR, Compound 75, CDCl3, 125 MHz 
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1
H NMR, Compound 76, CDCl3, 500 MHz 
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13
C NMR, Compound 76, CDCl3, 125 MHz 
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1
H NMR, Compound 82, CDCl3, 500 MHz 
111 
 
 
13
C NMR, Compound 82, CDCl3, 125 MHz 
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Impurity 
1
H NMR, Compound (+)-74, CDCl3, 500 MHz 
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Impurity 
13
C NMR, Compound (+)-74, CDCl3, 500 MHz 
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3.11. Chromatograms for Selected Compounds 
3.11.1. HPLC chromatograms for compounds 39  
(jal-1-163) 
Normal phase HPLC of 1
st
 generation Tripeptide 39 
Altima® C18 10μ, 10 x 250 mm column 
 
 
 
 
 
 
 
 
 
Time 
(min) 
Flow 
(mL 
min
-1
) 
Water 
(%) 
MeCN 
(%) 
0.01 3.00 65.0 35.0 
23.00 3.00 30.0 70.0 
26.00 3.00 5.0 95.0 
31.00 3.00 50.0 50.0 
33.00 3.00 50.0 50.0 
35.00 3.00 50.0 50.0 
 Retention Time Area % Area Height Int Type 
1 13.062 1072371 20.76 91509 bb 
2 13.480 1146574 22.20 106666 bb 
3 13.912 2946252 57.04 252700 bb 
Detection at 218 nm 
Detection at 254 nm 
Method-Gradient 
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Normal phase HPLC of 2
nd
 generation Tripeptide 39 (jal-2-133) 
Altima® silica 10μ, 10 x 250 mm column 
 
 
 
 
 
 
Time 
(min) 
Flow 
(mL 
min-1) 
H2O 
(%) 
MeCN 
(%) 
0.01 3.00 75.0 25.0 
14.00 3.00 35.0 65.0 
17.00 3.00 5.0 95.0 
21.00 3.00 50.0 50.0 
23.00 3.00 50.0 50.0 
25.00 3.00 50.0 50.0 
 Retention Time Area % Area Height Int Type 
1 14.151 30250183 40.87 2170291 BV 
2 14.737 43766640 59.13 2174022 VB 
Method-Gradient 
Detection at 218 nm 
Detection at 254 nm 
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3.11.3. Chiral HPLC of Fmoc-D-Cys(ethanol)-OAll 75 (jal-7-005) 
Chiralcel OD-H column from Daicel; 4.6 x 25 mm 
Method-Isocratic 20% isopropanol 80% n-hexane (1 mL min
-1
) 
 
 
 
Detection at 254 nm 
Detection at 218 nm 
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3.11.4. Chiral HPLC of Mosher’s-Cys(ethanol)-OAll 76 (jal-7-012) 
Chiralcel OD-H column from Daicel; 4.6 x 25 mm 
Method-Isocratic 10% isopropanol 90% n-hexane (1 mL min
-1
) 
 Retention 
Time 
Area % Area Height Int Type Peak Type 
1 13.210 5229150 5.07 100061 bb Unknown 
2 15.737 97970744 94.93 1320891 bb Unknown 
 
 
 
 
 
 
 
 
 
 
 
 
Detection at 218 nm 
Detection at 254 nm 
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3.11.5. Chiral HPLC of Pht-Cys(ethanol)-OAll (±)74 (jal-6-194) 
Chiralcel OD-H column from Daicel; 4.6 x 25 mm 
Method-Isocratic 20% isopropanol 80% n-hexane (1 mL min
-1
) 
 Retention 
Time 
Area % Area Height Int Type Peak Type 
1 10.125 55594596 53.15 1232491 Bb Unknown 
2 13.721 49009114 46.85 794789 bb Unknown 
 
 
Detection at 218 nm 
Detection at 254 nm 
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3.11.6. Chiral HPLC of Pht-D-Cys(ethanol)-OAll (+)-74 (jal-7-055) 
Chiralcel OD-H column from Daicel; 4.6 x 25 mm 
Method-Isocratic 20% isopropanol 80% n-hexane (1 mL min
-1
) 
 Retention 
Time 
Area % Area Height Int Type Peak Type 
1 9.686 43476249 91.43 1165981 bb Unknown 
2 11.986 4074011 8.57 106167 bb Unknown 
 
 
Detection at 218 nm 
Detection at 254 nm 
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Chapter 4. Peptidyl Thioenamide Synthesis and Macrocyclization 
4.1. Imidazolidinone: a Thioenamide Interrupted  
 Optimization of thioenamide formation using acetamide, featured in Chapter 2, paved the 
way for this transformation in the context of a peptide framework.  This extrapolation required 
careful consideration of protection strategy (i.e. PG) on the amine group of the amide coupling 
partner (Scheme 4.1).   
 
Scheme 4.1. Reaction of aldehyde 56 with an α-amino amide 
The protecting group would need to weather the Lewis acid and prolonged heating required to 
produce the desired product.  Additionally, we sought a group that could be easily removed, to 
liberate the free amine, and proceed to coupling with another amino acid.  Given the lack of 
chemistry that has been performed in the presence of aminovinyl-cysteine, the stability of its 
thioenamide functionality towards reaction conditions in general was a complete unknown. 
 We learned an early lesson from α-amino amide couplings with Fmoc-protected 
alaninamide 63 (Scheme 4.2).  At this time we were still using protic acids to achieve 
thioenamide formation.  Our original plan was to use alaninamide in place of a cysteinamide to 
produce a model system of the microbisporicins (Fig. 4.1).  Exploring Fmoc protection for the 
amine made sense, as this group is ubiquitous in peptide chemistry and can often be easily 
removed.  To our surprise, when we attempted to form thioenamide 65 from acetal 28 and 
alaninamide 63, we did not observe any desired product at all.  Instead, we isolated 
imidazolidinone 64 in 67% yield (Scheme 4.2).   
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Figure 4.1. Microbisporicin E ring and proposed model system 
This side product results from attack of the Fmoc-carbamate nitrogen on a transient carbocation 
that forms before elimination takes place (See Section 3.2). 
 
Scheme 4.2. Abridged mechanism of formation of imidazolidinone 64 and comparison with 
potential imine 81 
 
The structure of imidazolidinone 64 eluded us for a while, as the NMR was difficult to 
interpret and the molecular ion observed by HRMS is consistent with not only desired 
thioenamide 65 but also imine 81.  The key to identification of this product was the comparison 
of the carbon and proton chemical shifts expected for an imidazolidinone and an imine.  In the 
case of an N-acyl imine, the sp
2
 CH (colored red in 81 in scheme 4.2) would be expected to give 
rise to a signal at 7.5-8.0 ppm in the proteon NMR, correlated to a 
13
C signal at 190-170 ppm.
1
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In contrast, our compound displayed a proton signal 5.20 ppm correlated to a 
13
C NMR signal at 
69.0 ppm via HSQC, pointing strongly towards imidazolidinone 64.  
This result was further confirmed by analogous reaction between benzaldehyde (82) and 
Fmoc-alaninamide 63 (Scheme 4.3) in the presence of boron trifluoride diethyl etherate.  The 
resulting imidazolidinone 83 was obtained in 75% yield, and could be much more easily 
characterized than cysteine derivative 64.  The reaction also showed that the transformation takes 
place with both protic and Lewis acids, as expected.  
 
Scheme 4.3. Imidazolidinone formation with benzaldehyde 
The fact that the rate of attack of a poorly nucleophilic, carbamate nitrogen is fast enough 
to intercept thioenamide formation, showed us that nucleophilicity at this site is intolerable.  
Thus, any amino amide coupling partner must be doubly protected at the amine nitrogen.   
4.2. Double Amine Protection – Benzyl Groups 
 We began our investigation into doubly protected amines by modifying alaninamide.  
The first strategy we used was appendage of the para-methoxybenzyl group, viz. 84 (Scheme 
4.4), hoping to leverage the mild acidic or oxidative conditions with which it can be removed.  
To our disappointment, the Lewis acidic conditions used to form thioenamide quickly removed 
the para-methoxybenzyl group and the reaction proceeded to yield imidazolidinone 64 yet again.  
The next group surveyed was the less acid labile benzyl group in alaninamide 85.  As expected, 
the benzyl group was not removed by the acidic conditions.  Nevertheless, no thioenamide was 
generated by the reaction.  Instead, bis-amide 86 was isolated in 25% yield.   
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Scheme 4.4. Condensation of acetal 28 with backbone benzyl protected alaninamides 
At about this stage in our studies, based on optimization of the reaction with acetamide 
(See Chapter 2), we switched to boric acid and increased the temperature of the reaction to 
minimize formation of bis-amide 86.  The reaction was still sluggish in toluene (b.p. 110 °C); we 
switched to xylenes (b.p. 140 °C) to good effect (Scheme 4.5).  With these changes, we 
synthesized our first “dipeptide” thioenamide 87 in 52% yield.  No E-isomer could be detected in 
the crude product mixture via HPLC.   
 
Scheme 4.5. Formation of thioenamide 87 
 At this point we switched from alaninamide to valinamide, to begin our synthesis of the 
C-terminal ring of cypemycin (See Chapter 1, Fig. 1.10).  Removal of benzyl protecting groups 
is typically achieved by reduction of carbon-heteroatom bonds via reductive hydrogenolysis.  
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These conditions held the potential to reduce our thioenamide, and hence the benzyl group was 
not ideal.  We found that the para-methoxybenzyl group was stable to boric acid, so we reverted 
to this protecting group that had not held up to BF3•OEt2.  With this strategy we synthesized 
valine thioenamide 89 and began attempts to deprotect the α-amine to afford secondary amine 90 
(Scheme 4.6). 
 
Scheme 4.6. Formation of and removal of fmoc from thioenamide 89 
 Curiously, standard conditions for Fmoc removal (piperidine or diethylamine) did not 
liberate the secondary amine.  Removal was possible with a stronger base (DBU), but the 
reaction required careful monitoring and low temperature.  Even with these considerations, the 
yield was never more than 50%.  The poor yield was, in part, due to abstraction of the AviCys α 
proton (Scheme 4.7).  This issue was deduced through characterization “dimer” 92 that arises 
from elimination to form a reactive enethiolate anion analogous to that in the biosynthesis of 
AviCys (See Chapter 1, Scheme 1.1).  Mechanistically, methylene bridged “dimer” 92 arises 
from two attacks of enethiolate 91 on dichloromethane, employed as the solvent for the reaction 
(Scheme 4.7).  The yield of dimer 92 was as high as 38%, though this could be reduced by 
quenching the reaction with aqueous HCl before concentration.  Nonetheless, this elimination 
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pathway opened up too much potential for epimerization of our AviCys Cα stereocenter to 
continue the pursuit of base labile protecting groups. 
 
Scheme 4. 7. Mechanism for formation of "dimer" 92 
4.3. Tetrachlorophthalimide (Tcp) 
 We needed to move away from Fmoc chemistry, yet wanted to stick with well-
established carbamate protecting groups that could be removed under acidic or neutral 
conditions.  In this vein, we attempted to generate both the Boc (94) and Cbz (95) variants of 
para-methoxybenzyl (PMB) valinamide 88 (Scheme 4.8).  To our surprise, the Cbz group could 
not be installed on PMB amine 93 and, less surprisingly, PMB could not be installed on a Cbz 
carbamate.  We were, however, able to install a Boc carbamate as the second protecting group 
and generate thioenamide 96, but only in low yield.  Efforts to increase the yield of 96 were 
unsuccessful. 
 
Scheme 4.8. Boc and Cbz in combination with PMB for a-amine double protection 
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 The poor results from bis-protection of our valinamide pressed us to think about divalent 
protection that could be removed in a single step.  We turned our attention to 
tetrachlorophthalimido (Tcp) protection.  While we could not find reports of its use in complex 
peptide chemistry, it has been used recently in medicinal
2
 and glycoside
3
 chemistry (Scheme 
4.9).  Munday et al. installed the Tcp group using Mitsunobu conditions and removed it with 
methyl amine in good yields for both transformations (Scheme 4.9A).  Panza et al., in contrast, 
used tetrachlorophthalic anhydride to install the group. However, they were unable to efficiently 
remove the group without degradation of their material (Scheme 4.9B).   
 
Scheme 4.9. Recent examples of Tcp utilization 
We readily synthesized tetrachlorophthalimido-protected valinamide 106 from 
commercially available tetrachlorophthalic anhydride (102) (Scheme 4.10).  Due to the non-
acidic nature of the valinamide α-proton, we were able to safely use the basic conditions that 
caused the epimerization issue featured in Chapter 3.  We were very pleased to find that Tcp-
valinamide 106 was our most efficient coupling partner yet, yielding thioenamide 62 in 71% 
yield, while maintaining the favorable 8:1 Z:E ratio.   
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Scheme 4.10. Synthesis of Tcp-valinamide 106 and thioenamide 107 
Two reports from Fraser-Reid and coworkers gave us hope that the 
tetrachlorophthalimido (Tcp) group could be selectively removed in the presence of our 
unsubstituted phthalimide (Pht).
4,5 
 They used ethylenediamine in excess to remove the Tcp 
group, and then immediately aceylated with acetic anhydride in both cases (Scheme 4.11).  
While both reactions demonstrate that the Tcp can be removed chemoselectively, only one 
example discriminates between the two protecting groups within the same molecule.  In the case 
of intramolecular selectivity (Scheme 4.11B), Fraser-Reid had to reduce the equivalents of 
ethylenediamine from 4.5 to just 1.9, presumably due to partial removal of the Pht group.  These 
two examples, from the same group, were the only literature precedent available for 
chemoselective removal of the Tcp protecting group in the presence of the Pht group.    
 For our desired transformation, excess ethylenediamine at room temperature in ethanol 
was ineffective.  Bringing the reaction to reflux could force a reaction with our substrate, but the 
crude 
1
H NMR and TLC quickly became complicated and the risk of epimerization with such a 
basic reagent at high temperature was untenable.  Another common reagent used for the removal 
of phthalimido protecting groups is hydrazine, which is less basic than ethylenediamine by 
nearly two orders of magnitude (pKa of conjugate acids: ethylenediamine = 9.98, hydrazine = 
8.10).  We found that hydrazine gave rise to a cleaner reaction profile, even under reflux.   
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Scheme 4.11. Fraser-Reid's precedents for selective removal of Tcp in presence of Pht 
  Using hydrazine in similar excess (1.9 equivalents) at elevated temperature, we observed 
a rapid reaction, with conversion to a single major product in high yield.  We were never able to 
isolate free amine at this point, however, mass spectrometry of the crude product showed the free 
amine product as the major ion (m/z 432).  Following Fraser-Reid’s precedent, we proceeded to 
acylate the free amine in situ with Boc-Leu-OH to give what appeared to be a nearly quantitative 
yield of desired product 113 (Scheme 4.12).  The 
1
H NMR of the isolated product was quite 
complicated and difficult to interpret, but evidence of all three amino acids (Cys, Val, Leu) was 
apparent, along with an intact thioenamide.  Nevertheless, the desired mass was never observed.  
This was a warning sign that something had gone awry in the sequence of reactions.  Detailed 
NMR analysis using 2D methods (COSY, HSQC, HMBC, etc.) was required to solve this issue. 
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Scheme 4.12. Stalled Tcp removal and the synthesis of "false" peptide 116 
Ultimately the data for the compound could be explained by an “interrupted Tcp 
removal” (Scheme 4.12).  The product of our reaction was not the desired leucine amide 113, but 
the diacyl hydrazide 116.  This resulted from premature coupling of leucine to a partially 
removed Tcp.  The resulting side product would show only a single proton difference from our 
desired product via 
1
H NMR, and this lone hydrazide proton exchanges, at least partially, with 
deuterium in the deuterated methanol that was used for analysis.  Carbon-13 NMR and 
correlation information from HSQC and HMBC were the only methods that could fully elucidate 
the structure of this strange product. 
The desired free amine, for which we thought we had observed the molecular ion via 
mass spectrometry could also be explained by a long-lived hydrazide intermediate (Scheme 
4.12).  While the ring-opened Tcp 114 could be observed in the mass data (m/z signal centered at 
732), it was always a small signal.  The fact that the major ion was free amine points to a facile 
fragmentation that takes place during ionization.  This could result in a radical species that 
abstracts a proton to generate amine 117 within the instrument.  With such strong evidence for 
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partial removal of the Tcp group taking place, the next task was to alter the reaction conditions to 
generate genuine free amine 117.   
 
Scheme 4.13. Explanation for a base peak in mass spectrometry corresponding to desired amine 
117 
  
Our experience with “false peptide” 116 gave us insight into the relative rates of the two 
steps required for complete Tcp removal.  The initial attack of hydrazine is very fast, and 
chemoselective for the Tcp over the Pht (Scheme 4.14).  The other required step, an 
intramolecular attack to form a 6-membered hydrazide ring, is much slower.  The natural 
assumption was that using a single equivalent of hydrazine could achieve this transformation, 
given enough time and heat.  Although it is unclear why, we found that in order to proceed past 
hydrazide 114 an excess of hydrazine was required.  When hydrazine was used in great excess 
(10% v/v in ethanol), the unsubstituted phthalimido (Pht) was be fully cleaved as well.  Even 
when just 1.8 equivalents of hydrazine were used, partial removal of the Pht group was observed.  
Using isolated hydrazide 114, we investigated the crucial second step of the process.  
Unfortunately, the isolated yield of hydrazide 114 was always low and all attempts to form free 
amine 117 from it were low yielding as well.  
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Scheme 4.14. Relative rates of Tcp and Pht attack 
 The key to generating free amine 117 was, following the initial formation of 114, to 
eliminate the nucleophilicity of hydrazine before it could attack the Pht.  Several examples in 
recent literature utilize acidification in order to trap the resulting amine as a cation.
6-8
  With 
acidification of the reaction, as soon after the first attack as possible, we would protonate any 
excess hydrazine still present and prevent further attack.  Our early attempts with acidification 
used 2.5 equivalents of hydrazine in ethanol at reflux.  After an hour we added aqueous 
hydrochloric acid and were able to isolate free amine 117.  However, only very low yields were 
achieved via this method and often the product was mixed with 120 resulting from reduction of 
the thioenamide.  This mixture was inferred from a complicated 
1
H NMR, low integration value 
for the protons of the thioenamide functional group, and the observed mass value for a reduced 
product. 
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Scheme 4.15. Isolation of free amine 117 mixed with reduced product 120 
 Hydrazine forms diimide (HN=NH) over time, and this impurity has previously been 
noted to cause problematic reductions during Pht removal.
9
  Reduction by diimide has been 
avoided by introducing an excess of a sacrificial alkene.  Indeed, including 2 equivalents of allyl 
alcohol in our reaction mixture prevented the occurrence of reduced product 120.  We carefully 
monitored the initial hydrazine attack via 
1
H NMR, watching for the disappearance of a signal at 
4.49 ppm corresponding to the valine α-proton in 62, to determine both the best time to quench 
the reaction with acid and the minimum amount of hydrazine required to consume the starting 
material.  With these insights we settled on the conditions shown in Scheme 4.16, using 1.8 
equivalents of hydrazine and a reaction time of 1.5h, then cooling the reaction and acidifying 
with dilute, aqueous hydrochloric acid.  This was followed by a work-up using aqueous sodium 
bicarbonate to neutralize the HCl and direct coupling with leucine to generate peptide 113 in 
41% over the three steps, putting us a big step closer to our macrocyclization.  However, the 
conditions for Tcp removal and peptide coupling led to partial erosion of the stereochemistry.  
Peptide 113 shows a 3:1 ratio of diasteremeric species, despite entering the reaction with only 8-
15% of the undesired diastereomer. 
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Scheme 4.16. Successful Tcp removal and coupling of Boc-Leu-OH 
4.4. Acid and Amine Deprotection 
 The next step en route to macrocyclization was to remove the protecting groups at each 
terminus: the allyl ester and the Boc carbamate, revealing the acid and amine respectively.  We 
investigated each of these reactions separately, in an effort to determine the optimal order of 
events.   
4.4.1. Boc Removal 
We began with removal of the Boc protection, using triflouroacetic acid (TFA) and 
triethylsilane (TES) as a cation scavenger (Scheme 4.17).  While the transformation readily took 
place, we again isolated a reduced variant of our desired product.  This side product could only 
be isolated via RP-HPLC, showed no thioenamide protons, and electrospray mass spectrometry 
displayed an [M+2] ion relative to desired free amine 121.  Triethylsilane is known to reduce 
double bonds, so this was the likely culprit at this step.  Switching the cation scavenger to 
thioanisole) prevented this side reaction (Table 4.1).  While no yield was recorded at this point, 
the crude HPLC trace and 
1
H NMR clearly showed an improvement over triethylsilane. 
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Table 4.1. Boc Removal 
 
Entry Reductant Result 
1 TES Mix of 121 & 122 
2 thioanisole 121 only 
 
4.4.2. Allyl Ester Removal 
 We probed removal of the allyl ester from fully protected peptide 113.  Conventional 
conditions for allyl ester removal are catalytic palladium (0) with an allyl scavenger, often 
morpholine or barbituric acid.  We observed the desired transformation, under traditional 
conditions.  However, the RP-HPLC trace showed two major products and recovery of desired 
free acid from the instrument was very low. 
 
Scheme 4.17. Allyl removal with barbituric acid 
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 The major side product had a strikingly similar structure to desired acid 123 according to 
NMR, though the mass was m/z 16 amu higher than the desired free acid.  This led us to 
conclude that our compound had been oxidized, with by far the most likely position being the 
sulfur atom of our thioenamide (Figure 4.2). 
 
 
Figure 4.2. Separation of 123 and oxidized by product 124 
 This oxidation product accounted for roughly 50% of the material, so it was imperative 
that we shut down this reaction pathway.  Inspired by the sacrificial olefin used in our Tcp 
removal, we sought a reagent that could be oxidized preferentially over our desired compound.  
There were reports of thiosalicylic acid being used as an allyl scavenger during this type of 
transformation with allyl amines (Scheme 4.18).
10,11
   
RP-HPLC, 0 to 95% MeCN in H2O (0.1% TFA)  
4 mL min-1 Detection at 254 nm  
Column- Altima 10 µm, C18 (250 mm × 10 mm) 
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Scheme 4.18. Deallylations using thiosalicyclic acid 
We were hopeful that thiosalicylic acid could serve us as both an allyl scavenger and a 
sacrificial reductant when used in excess.  Indeed, when this reagent was substituted for 
barbituric acid, we observed only trace amounts of oxidized thioenamide (Scheme 4.19). 
 
Scheme 4.19. Allyl removal with thiosalicylic acid 
4.5. Free Amino Acid Tripeptide 
With both deprotection reactions optimized, for compatibility with the thioenamide 
functional group, it was now time to determine the most effective order of events to generate free 
amino acid peptide 127.  Either way, RP-HPLC was required for chromatographic purification, 
and the recovery was very low. 
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Figure 4.3. RP-HPLC chromatogram showing decrease in oxidized thioenamide 
    During an aqueous work-up, prior to RP-HPLC, we found that amino acid peptide 127 
was almost completely retained in the aqueous layer.  We back-extracted peptide 127 into the 
aqueous layer, making use of the compound’s high water solubility.  Freezedrying this extract 
gave remarkably clean peptide 127, with some remaining thiosalicyclic acid  With this semi-
purification, we were able to remove both the Boc and allyl protecting groups and acquire 
peptide 127 in acceptable purity (Scheme 4.20). 
 
Scheme 4.20. Optimized liberation of free amino acid peptide 127 
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4.6. Macrocycle 
4.6.1. Macrolactamization 
With linear peptide 127 in-hand, we were a single, intramolecular amide bond formation 
away from a phthalimido-capped cypemycin C-terminal ring.  Although we had previously 
attempted macrocyclizations on the small amount of 127 isolated from RP-HPLC, no desired 
macrocycle had ever been observed.  An increase in the amount of material from our optimized 
synthesis and purification of 127 breathed new life into this effort. 
 As expected, starting material concentration played a crucial role.  When the reaction was 
run at a relatively high concentration (0.012 M in DMF), no desired macrocycle was observed.  
If more dilute conditions were used (0.002 M in DMF), then desired product was generated 
(Scheme 4.21).   
 
Scheme 4.21. Synthesis of macrocycle 128 
 Purification of macrocycle 128 was difficult via flash chromatography due to impurities 
that elute very closely.  A high purity sample was obtained by RP-HPLC (Figure 4.4) in 20% 
yield of over three steps, with a single chromatographic purification.  
4.6.2. Characterization 
 Full structural characterization was possible at this stage, with the use of mass 
spectrometry, 
1
H NMR, COSY, and HSQC.  All amino acids were accounted for, and we 
observed the correct mass.  Figure 4.5 shows the full 
1
H NMR with all peaks labeled.   
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Figure 4.4. RP-HPLC chromatogram of crude macrocyclization product mixture 
The coupling constants for the native cypemycin AviCys moiety were not reported,
12
 so our 
synthetic material has afforded this data for the first time.  We can plainly observe the coupling 
constants for the olefin and amide; 7.0 Hz and 10.8 Hz respectively.  Additionally, our 
macrocyclization hints at a propensity for the peptide with the D-cysteine configuration in 127 to 
cyclize more readily than the undesired diastereomer with the L-cysteine.  Though we entered 
into the cyclization with roughly 25% of the undesired Cys(Avi) stereoisomer in linear 127, we 
have only observed a single diastereomer of 128.  
This is, to date, the first synthesis of a 13-membered AviCys-containing macrocycle.  
Hence, it is also the first synthesis of an N-capped cypemycin C-terminal ring.  These facts 
afford us the opportunity to break ground on the characterization of such cyclic systems.   
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Figure 4.5. 1H NMR spectrum of macrocycle 128 [See Table 4.2 for full assignments] 
We compared the data for macrocycle 128 with reported values for the C-terminal ring of 
isolated cypemycin (Table 4.2).  Our values for the leucine moiety match up nicely, though 
moderate differences exist in both the Cys(Avi) and valine residues.  This difference can likely 
be explained by solvent effects and the electronic changes the phthalimido protection introduces, 
as well as the impact of the peptide tail in the native peptide.      
4.7. Future Work 
 Work on the detailed characterization of macrocycle 128 will continue.  Specifically, we 
will use variable temperature NMR and NOESY to determine the preferred conformation.  
Variable temperature experiments will elucidate the hydrogen bonding of the amide protons 
when run in DMSO-d6 or 10% D2O in water.  This information, along with NOESY correlation 
peaks, will help us to paint a full picture of the conformation in solution.  We will also study the 
removal of the Pht group to liberate free amine 129 (Scheme 4.22). 
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Table 4.2. Comparison of macrocycle 128 NMR (CD3OD, 500 MHz, 25 °C) with cypemycin 
Ref. 12 (DMSO-d6, 400 MHz, 30 °C) 
 
    Proton (ppm) Carbon (ppm) 
    Ref. 12 128 Ref. 12 128 
Cys(Avi) CON-H 7.65 N/A 169.42 Unknown 
  α 4.64 5.29 52.05 55.16 
  β 3.08, 2.85 3.47, 3.12 37.04 37.15 
  1' 5.47 5.54 99.84 101.27 
  2' 7.11 7.23 132.09 134.42 
  N-3' 8.7 9.07 N/A N/A 
Leu CON-H 7.46 Unknown 172.38 Unknown 
  α 3.93 4.13 54.9 57.1 
  β 1.63, 1.48 1.63, 1.51 39.38 40.61 
  γ 1.63 1.67 24.2 25.7 
  δ 0.93 0.91 22.27 22.82 
    0.84 0.89 21.69 21.61 
Val CON-H 7.71 Unknown 169.01 Unknown 
  α 3.92 4.11 59.57 63.05 
  β 2.05 2.45 28.51 30.31 
  γ 0.78 1.12 18.9 19.82 
    0.89 1.07 19.47 19.51 
 
 
Scheme 4. 22. Removal of Pht 
 The above experiments will be followed by the total synthesis of cypemyin (Scheme 
4.23).  Solid phase peptide synthesis (SPPS) will be used to generate 18-mer peptide 130.  This 
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will then be coupled to free amine macrocycle 129, completing the first total synthesis of 
cypemycin.  This would represent the first total synthesis of any AviCys-containing peptide to 
date.     
 
Scheme 4.23. Total synthesis of cypemycin 
4.8. Experimental Procedures 
4.8.1. General Methods As is 2.7.1 
4.8.2. Formation of thioenamide 87 (Scheme 4.5) 
Dipeptide thioenamide (±)-87. Boric acid (37 mg, 0.60 mmol, 5.0 equiv.) and Fmoc(Bn)-Ala-
NH2 (85) (48 mg, 0.120 mmol, 1.0 equiv.) were added to a solution of (±)-56 (40 mg, 0.120 
mmol, 1.0 equiv.) in xylenes (40 mL).  This mixture was brought to reflux for 24 h.  Additional 
Fmoc(Bn)-Ala-NH2 (85) (48 mg, 1.0 equiv.) was added and the reaction was continued at reflux 
for an additional 16 h.  The mixture was concentrated and the crude residue was subjected to 
flash chromatography, eluting with 5:1 hexanes-EtOAc to isolate Z-87 (45 mg, 52%) as a yellow 
solid and a mixture of diastereomers at cysteine Cα.  Rf 0.27 (2:1 hexanes-EtOAc). 
1
H NMR 
(400 MHz, CDCl3) δ 1.30 (br s, 3H), 3.33-3.53 (m, 2H), 4.17 (dd, J = 12.3, 6.0 Hz, 1H), 4.30 (d, 
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J = 6.0 Hz, 0.5H), 4.34 (d, J = 6.0 Hz, 0.5H), 4.40-4.73 (m, 4H), 4.64 (d, J = 5.7 Hz, 2H), 4.99 
(dd, J = 10.6, 4.2 Hz, 1H), 5.17-5.25 (m, 2H), 5.29 (br s, 2H), 5.78-5.89 (m, 1H), 6.83 (app. t, J = 
8.1 Hz, 0.5H), 6.93 (app. t, J = 8.0 Hz, 0.5H), 7.05-7.54 (m, 10H), 7.67-7.73 (m, 4H), 7.82 (d, J 
= 2.9 Hz, 1H), 7.89 (d, J = 3.0 Hz, 1H), 8.29 (br s, 1H); 
13
C NMR (125 MHz, CDCl3) δ 14.5, 
29.8, 33.5, 47.3, 52.4, 55.9, 66.9, 68.1, 101.0, 119.2, 120.1, 123.8, 125.0, 125.1, 127.2, 127.8 
(2C), 128.6, 128.8, 131.3, 131.4, 131.7, 131.8, 131.9, 134.3, 134.4, 134.5 (2C), 137.9, 138.1, 
141.4, 143.7, 143.8 (2C), 143.9, 167.5, 167.6, 167.7. HRMS (ESI) calcd for C41H38N3O7S 
(M+H)
+
: calcd 716.2425; obsd 716.2420.  
4.8.3. Synthesis of thioenamide (±)-89 (Scheme 4.6) 
Dipeptide thioenamide (±)-89. Boric acid (19 mg, 0.32 mmol, 5.0 equiv.) and Fmoc(Bn)-Ala-
NH2 (88) (29 mg, 0.06 mmol, 1.0 equiv.) were added to a solution of (±)-56 (21 mg, 0.06 mmol, 
1.0 equiv.) in xylenes (21 mL).  This mixture was brought to reflux for 24 h.  Additional 
Fmoc(PMB)-Ala-NH2 (88) (29 mg, 1.0 equiv.) was added and the reaction was continued at 
reflux for an additional 16 h.  The mixture was concentrated and the crude residue was subjected 
to flash chromatography, eluting with 5:1 hexanes-EtOAc to isolate Z-89 (23 mg, 47%) as a 
yellow solid and a mixture of diastereomers at cysteine Cα.  Rf 0.60 (1:1 hexanes-EtOAc). 
1
H 
NMR (500 MHz, CDCl3) δ 0.53 (d, J = 4.9 Hz, 1.5H), 0.59 (d, J = 4.4 Hz, 1.5H), 0.87 (d, J = 5.8 
Hz, 1.5H), 0.91 (d, J = 4.7 Hz, 1.5H), 2.46 (br s, 1H), 3.19 (d, J = 14.5 Hz, 0.25H), 3.19 (d, J = 
14.6 Hz, 0.25H), 3.22-3.65 (m, 2.5H), 3.76 (s, 3H), 4.02 (d, J = 15.3 Hz, 0.5H), 4.11 (d, J = 15.3 
Hz, 0.5H), 4.15-4.24 (m, 1H), 4.26 (d, J = 15.3 Hz, 0.5H), 4.32 (d, J = 15.3 Hz, 0.5H), 4.57 (d, J 
= 4.7 Hz, 1H), 4.60-4.74 (m, 3H), 4.95-5.07 (m, 1H), 5.16-5.32 (m, 3H), 5.80-5.91 (m, 1H), 6.70 
(d, J = 6.4 Hz, 2H), 6.86 (d, J = 6.4 Hz, 1H), 6.79-6.97 (m, 1H), 7.23-7.32 (m, 2H), 7.34-7.41 
(m, 1H), 7.44-7.57 (m, 1H), 7.60-7.95 (m, 7H), 8.74 (br s, 0.5H), 8.95 (br s, 0.5H);
 13
C NMR 
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(125 MHz, CDCl3) δ 19.3, 20.1, 27.0, 29.8, 30.6, 33.3, 33.5, 40.6, 47.5, 50.8, 52.2, 52.4, 53.6, 
55.3, 66.8, 66.9, 67.5, 101.1, 101.4, 113.8 (2C), 119.2 (2C), 120.1 (2C), 123.8 (2C), 123.9, 124.9 
(2C), 127.3, 127.8, 128.1, 128.3, 129.5, 129.6, 131.2, 131.3, 131.8, 134.3, 134.4, 134.5, 141.5, 
141.6, 143.9, 144.0, 158.9, 159.0, 167.5 (2C), 167.6 HRMS (ESI) calcd for C44H44N3O8S 
(M+H)
+
: calcd 774.2844; obsd 774.2843.   
4.8.4. Synthesis of methylene-bridged “dimer” 92 (Scheme 4.7) 
Methylene-bridged dimer 92. DBU (3.8 µL, 3.8 mg, 0.025 mmol, 1.5 equiv.) was added to a 
solution of thioenamide 90 (13 mg, 0.0168 mmol, 1.0 equiv.) in DCM (5 mL) at 0 °C.  After 4 h, 
piperidine (8.3 µL, 7.2 mg, 0.084 mmol, 5.0 equiv.) was added dropwise and the solution was 
immediately concentrated.  The residue was subjected to flash chromatography, eluting with 
5:13:1 hexanes-EtOAc to isolate 92 (4 mg, 40%) as a colorless solid.  Rf 0.38 (2:1 hexanes-
EtOAc).
  1
H NMR (500 MHz, CDCl3) δ 0.87 (d, J = 7.0 Hz, 6H), 0.96 (d, J = 7.0 Hz, 6H), 2.14 
(sept, J = 4.4 Hz, 2H), 3.06 (d, J = 4.4 Hz, 2H), 3.59 (d, J = 12.7 Hz, 2H), 3.73 (d, J = 12.7 Hz, 
2H), 3.80 (s, 6H), 3.83 (s, 2H), 5.45 (d, J = 7.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 4H), 7.15 (dd, J = 
11.7, 7.5 Hz, 2H), 7.28 (d, J = 8.6 Hz, 4H), 9.62 (d, J = 11.7 Hz, 2H); 
13
C NMR (125 MHz, 
CDCl3) δ 17.9, 19.7, 31.6, 40.3, 53.4, 55.4, 67.8, 100.9, 114.1, 127.6, 129.7, 131.4, 159.1, 171.6.  
HRMS (ESI) calcd for C31H45N4O4S2 (M+H)
+
: calcd 601.2877; obsd 601.2877. 
4.8.5. Synthesis of “false peptide” 116 from stalled Tcp removal (Scheme 4.12) 
“False Peptide” 116. Hydrazine (1.1 µL, 1.1 mg, 0.024 mmol, 1.1 equiv.) was added to a 
solution of thioenamide (±)-62 (15 mg, 0.0214 mmol, 1.0 equiv.) in DMF (500 µL).  In a 
separate vessel, EDC (3.3 mg, 0.0214 mmol, 1.0 equiv.) and HOBt (3.3 mg, 0.214 mmol, 1.0 
equiv.) were added sequentially to a solution of Boc-L-Leu-OH (5.4 mg, 0.0214 mmol, 1.0 
equiv.) in DMF (400 µL).  After 30 min, the thioenamide solution was added dropwise to the 
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activated acid and allowed to stir under N2 for 16 h.  The mixture was diluted with EtOAc (100 
mL) and washed with 5% aq. citric acid (100 mL).  The aqueous layer was extracted a second 
time with EtOAc (75 mL) and the organic layers were combined, washed with brine (50 mL), 
filtered through MgSO4, concentrated, and the residue purified by flash chromatography eluting 
with 0.5->2% methanol in DCM to isolate “false peptide” 116 as a yellow oil (9 mg, 46%). Rf 
0.26 (5% methanol in DCM). 
1
H NMR* (500 MHz, CDCl3) δ 0.82-1.05 (m, 12H, obscured by 
impurity), 1.27-1.40 (m, 1H, obscured by impurity), 1.44 (s, 9H), 1.53-1.67 (m, 2H, obscured by 
impurity), 2.00-2.25 (m, 1H), 3.42-3.61 (m, 2H), 4.05-4.26 (m, 1H), 4.49 (d, J = 6.3 Hz, 0.3H), 
4.52 (d, J = 6.3 Hz, 0.3H), 4.57 (br s, 0.3H), 4.66 (d, J = 5.5 Hz, 2H), 5.03-5.17 (m, 1H), 5.19 (d, 
J = 10.5 Hz, 1H), 5.28 (dt, J = 17.2, 1.5 Hz, 1H), 5.38 (d, J = 7.8 Hz, 0.5H), 5.40 (d, J = 7.8 Hz, 
0.5H), 5.84-5.94 (m, 1H), 6.78-7.00 (m, 1H), 7.82-7.94 (m, 4H); 
13
C NMR (125 MHz, CDCl3) δ 
18.6, 19.9, 22.0, 23.4, 25.6, 25.8, 28.7, 28.8, 30.1, 30.8, 31.6, 40.2, 42.3, 53.1, 67.6, 80.6, 118.9, 
124.5, 124.7, 124.8, 132.9, 135.7, 135.9, 169.0, 169.3.  
*Contains multiple diastereomers and impurities 
4.8.6. Tcp removal and synthesis of thioenamide embedded peptide 113 
Tripeptide 113. Allyl alcohol (3.1 µL, 2.7 mg, 0.046 mmol, 2.0 equiv.) and hydrazine (2.1 mg, 
2.0 µL, 0.041 mmol, 1.8 equiv.) were added to a solution of (+) 62 (16 mg, 0.023 mmol, 1.0 
equiv.) in ethanol (3.0 mL).  The solution was brought to reflux and stirred for 1.5 h.  Aqueous 
HCl (0.5 M, 229 µL, 5.0 equiv.) was added and the solution was allowed to cool to rt and stir for 
16 h.  The mixture was diluted with EtOAc (100 mL) and washed with 5% aq. NaHCO3 (aq.) 
(100 mL).  The aqueous layer was extracted a second time with EtOAc (75 mL) and the organic 
layers were combined, washed with brine (50 mL), filtered through MgSO4 and concentrated.   
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A separate vessel, EDC (3.6 mg, 0.023 mmol, 1.0 equiv.) and HOBt (3.5 mg, 0.023 
mmol, 1.0 equiv.) were added to a solution of Boc-Leu-OH (5.7 mg, 0.023 mmol, 1.0 equiv.) in 
DMF (700 µL) and stirred for 30 min.  The crude concentrate from the Tcp removal was 
dissolved in DMF (500 µL) and added dropwise to the activated Boc-Leu-OH solution and left to 
stir under N2 for 16 h.  The mixture was diluted with EtOAc (100 mL) and washed with H2O 
(100 mL).  The aqueous layer was extracted a second time with EtOAc (75 mL) and the organic 
layers were combined, washed with brine (50 mL), filtered through MgSO4, concentrated, and 
the residue purified by flash chromatography eluting with 5:1->4:1 hexanes-EtOAc to isolate 
tripeptide 113 as a yellow oil (6 mg, 41%). Rf 0.46 (1:1 hexanes-EtOAc). 
1
H NMR* (500 MHz, 
CDCl3) δ 0.86 (d, J = 5.8 Hz, 3H), 0.88 (d, J = 6.1 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 
6.9 Hz, 3H), 1.45 (s, 9H), 1.46-1.53 (m, 1H), 1.55-1.84 (m, 2H), 2.18-2.37 (m, 1H), 3.43 (d, J = 
7.3 Hz, 1H), 3.46 (dd, J = 13.5, 10.6 Hz, 1H), 4.04-4.21 (m, 1H), 4.54 (dd, J = 8.6, 5.2 Hz, 1H), 
4.64-4.68 (m, 2H), 4.84-4.94 (m, 1H), 4.96 (app. t, J = 7.4 Hz, 1H), 5.23 (ddd, J = 10.4, 2.3, 1.1 
Hz, 1H), 5.25-5.32 (m, 2H), 5.81-5.91 (m, 1H), 6.88 (d, J = 7.2 Hz, 1H), 7.10 (dd, J = 11.0, 7.4 
Hz, 1H), 7.71-7.98 (m, 4H), 8.24 (d, J = 10.7 Hz, 1H); 
13
C NMR* (125 MHz, CDCl3) δ 17.5, 
19.4, 22.2, 23.0, 24.8, 28.4, 31.1, 34.4, 40.7, 52.8, 53.3, 58.3, 67.0, 101.5, 119.3, 124.1, 129.4, 
131.3, 131.7, 134.6, 134.7, 155.9, 167.5, 167.9, 168.9, 173.0. HRMS (ESI) calcd for 
C32H44N4O8S (M+H)
+
: calcd 645.2953; obsd 645.2963.  
*Mixture of diastereomers in a 3:1 ratio, data provided for the major, desired D-cysteine 
diastereomer 
4.8.7. Boc removal, allyl removal, and macrocyclization to form 128 (Scheme 4.21) 
Macrocycle 128. Thioanisole (3.7 µL, 3.9 mg, 0.031 mmol, 2.0 equiv.) and TFA (1.2 mL, 50% 
v/v) were added to a solution of tripeptide 113 (10 mg, 0.016 mmol, 1.0 equiv.) in DCM (8 mL) 
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at 0 °C.  This solution was stirred under N2 for 1 h.  The mixture was diluted with EtOAc (75 
mL) and washed with saturated aq. NaHCO3 (50 mL).  The aqueous layer was extracted a second 
time with EtOAc (50 mL) and the organic layers were combined, washed with brine (50 mL), 
filtered through MgSO4, concentrated.   
The residue as dissolved in THF (3 mL) and, to this solution, was added thiosalicylic acid 
(4.8 mg, 0.031 mmol, 2.0 equiv.) and Pd(PPh3)4 (1.8 mg, 0.0016 mmol, 0.1 equiv.).  The mixture 
was stirred under N2 for 15 min, concentrated and the residue dissolved in H2O (25 mL) and 
washed with CHCl3 (25 mL).  The aqueous extract was lyophilized to give crude amino acid 
tripeptide 127.  
Crude tripeptide 127 was dissolved in DMF (7.8 mL).  To this solution was added EDC 
(2.5 mg, 0.016 mmol, 1.0 equiv.) and HOBt (2.4 mg, 0.016 mmol, 1.0 equiv.).  The reaction was 
stirred under N2 for 16 h.  Water (200 mL) was added to the mixture and the solution was 
lyophilized.  The crude product was isolated by RP-HPLC (see conditions on p. 169) to give 
macrocycle 128 (1.5 mg, 20%) 
 1
H NMR (500 MHz, CD3OD) δ 0.89 (d, J = 6.9 Hz, 3H), 0.91 (d, 
J = 6.8 Hz, 3H), 1.07 (d, J = 6.7 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H), 1.46-1.73 (m, 3H), 2.40-2.52 
(m, 1H), 3.12 (dd, J = 14.6, 5.9 Hz, 1H), 3.43-3.50 (m, 1H), 4.07-4.17 (m, 2H), 5.29 (d, J = 5.2 
Hz, 1H), 5.54 (d, J = 7.0 Hz, 1H), 7.23 (dd, J = 10.8, 7.1 Hz, 1H), 7.80-7.95 (m, 1H), 7.92 (dd, J 
=  5.4, 3.1 Hz, 2H), 8.00 (dd, J = 5.4, 3.1 Hz, 2H), 9.07 (d, J = 10.8 Hz, 1H); 
13
C NMR data was 
inferred from inverse detection in the HSQC experiment (125 MHz, CD3OD) δ 19.5, 19.8, 21.6, 
22.8, 25.7, 30.3, 37.0, 40.6, 55.1, 57.1, 63.0, 101.3, 124.5 (2C), 134.4, 135.9. HRMS (ESI) calcd 
for C24H31N4O5S (M+H)
+
: calcd 487.2010; obsd 487.1998. 
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4.9. NMR Spectra 
1
H NMR Compound 87, CDCl3, 400 MHz 
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13
C NMR Compound 87, CDCl3, 125 MHz 
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1
H NMR, Compound 89, CDCl3, 500 MHz 
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13
C NMR, Compound 89, CDCl3, 125 MHz 
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1
H NMR, Compound 92, CDCl3, 500 MHz 
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13
C NMR, Compound 92, CDCl3, 125 MHz 
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1
H NMR, Compound 116, CD3OD, 500 MHz 
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13
C NMR, Compound 116, CD3OD, 125 MHz 
 
 
157 
 
1
H NMR, Compound 113 (3:1 mixture of diastereomers), CDCl3, 500 MHz 
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13
C NMR, Compound 113 (3:1 mixture of diastereomers), CDCl3, 125 MHz 
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1
H NMR, Compound 128, CD3OD, 500 MHz 
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HSQC NMR, Compound 128, CD3OD, 500 MHz 
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4.10. HPLC Chromatograms of Selected Compounds 
4.10.1. Compounds 123 & 124 (jal-6-109) 
Reverse phase HPLC following deallylation of  
113 with barbituric acid as allyl scavenger 
Altima® C18 10μ, 10 x 250 mm column 
 Retention 
Time 
Area % Area Height Int Type Peak Type 
1 23.967 30978120 46.33 1960167 bb Unknown 
2 25.463 35885509 53.67 2891870 bb Unknown 
 
 
 
 
 
 
  
Time 
(min) 
Flow 
(mL 
min
-1
) 
H2O 
% 
MeCN 
% 
0.01 4.00 100.0 0.0 
5.00 4.00 100.0 0.0 
8.00 4.00 85.0 15.0 
12.00 4.00 65.0 35.0 
20.00 4.00 40.0 60.0 
25.00 4.00 5.0 95.0 
30.00 4.00 5.0 95.0 
35.00 4.00 50.0 50.0 
40.00 4.00 90.0 10.0 
Detection at 254 nm 
Detection at 218 nm 
Method-Gradient 
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4.10.2. Reverse phase HPLC Chromatograms of  
Compounds 123 & 124 (jal-6-123) 
Reverse phase HPLC following deallylation of 113  
with thiosalicylic acid as allyl scavenger 
Altima® C18 10μ, 10 x 250 mm column 
 
  
Time 
(min) 
Flow 
(mL 
min
-1
) 
H2O 
% 
MeCN 
% 
0.01 4.00 100.0 0.0 
5.00 4.00 100.0 0.0 
8.00 4.00 85.0 15.0 
12.00 4.00 65.0 35.0 
20.00 4.00 40.0 60.0 
25.00 4.00 5.0 95.0 
30.00 4.00 5.0 95.0 
35.00 4.00 50.0 50.0 
40.00 4.00 90.0 10.0 
 Retention 
Time 
Area % Area Height Int Type Peak Type 
1 24.019 1188344 4.43 87943 bb Unknown 
2 25.293 25661725 95.57 3102395 bb Unknown 
Method-Gradient 
Detection at 254 nm 
Detection at 218 nm 
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4.10.3. Reverse phase HPLC of Compound 128 (jal-7-143) 
Altima® C18 10μ, 10 x 250 mm column 
 
 
 
 
 
 
  
Time 
(min) 
Flow (mL 
min
-1
) 
H2O 
% 
MeCN 
% 
0.01 3.00 60.0 40.0 
5.00 3.00 60.0 40.0 
8.00 3.00 50.0 50.0 
25.00 3.00 50.0 50.0 
27.00 3.00 25.0 75.0 
40.00 3.00 25.0 75.0 
42.00 3.00 5.0 95.0 
47.00 3.00 5.0 95.0 
Method-Gradient 
Detection at 254 nm 
Detection at 218 nm 
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4.11. Notes 
1. Chem 605 - Structure Determination Using Spectroscopic Methods.  Proton Chemical 
Shifts. https://www.chem.wisc.edu/areas/reich/nmr/h-data/hdata.htm (accessed August 
20th, 2019). 
2. Munday, R.H.; Goodman, L.; Noonan, G.M., “An Alternative Synthesis of the Lipophilc 
Tail Portion of Abediterol Using Linear-Selective Hydroformylation,” Tetrahedron Lett., 
2019, 60, 606-609. 
3. Panza, L.; Compostella, F.; Imperio, D., “A Versatile Synthesis of αGalCer and its 
Analogues Exploiting a Cyclic Carbonate as Phytosphingosine 3,4-Diol Protecting 
Group,” Carbohydr. Res., 2019, 472, 50-57. 
4. Debenham, J.S.; Madsen, R.; Roberts, C.; Fraser-Reid, B., “Two New Orthogonal 
Amine-Protecting Groups that can be Cleaved Under Mild or Neutral Conditions,” J. Am. 
Chem. Soc., 1995, 117, 3302-3303. 
5. Debenham, J.S.; Fraser-Reid, B., “Tetrachlorophthaloyl as a Versatile Amine Protecting 
Group,” J. Org. Chem., 1996, 61, 432-433. 
6. Tafelska-Kaczmarek, A.; Krzeminski, M.P.; Cwiklinska, M., “Asymmetric Synthesis of 
Benzofuryl β-Amino Alcohols by the Transfer Hydrogenation of α-Functionalized 
Ketones,” Tetrahedron, 2017, 73, 3883-3897. 
7. Battah, S.; Hider, R.C.; MacRobert, A.J.; Dobbin, P.S.; Zhou, T., “Hydroxypyridinone 
and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy,” J. Med. Chem., 
2017, 60, 3498-3510. 
8. De Simone, A.; Russo, D.; Ruda, G.F.; Micoli, A.; Ferraro, M.; Di Martino, R.M.C.; 
Ottonello, G.; Summa, M.; Armirotti, A.; Bandiera, T.; Cavalli, A.; Bottegoni, G., 
“Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional 
Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-
Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid 
Amide Hydrolase,” J. Med. Chem., 2017, 60, 2287-2304. 
9. Maryanoff, B.E.; Greco, M.N.; Zhang, H.C.; Andrade-Gordon, P.; Kaufman, J.A.; 
Nicolaou, K.C.; Liu, A.; Brungs, P.H., “Macrocyclic Peptide Inhibitors of Serine 
Proteases. Convergent Total Synthesis of Cyclotheonamides A and B via Late-Stage 
Primary Amine Intermediate. Study of Thrombin Inhibition under Diverse Conditions,” 
J. Am. Chem. Soc., 1995, 117, 1225-1239. 
10. Lemaire-Audoire, S.; Savignac, M.; Genet, J.P.; Bernard, J.M., “Selective Deprotection 
of Allyl Amines Using Palladium,” Tetrahedron Lett., 1995, 36, 1267-1270. 
11. Baldwin, I.C.; Briner, P.; Eastgate, M.D.; Fox, D.J.; Warren, S., “Synthesis of 
Enantiomerically Pure 2,2,3,4,5-Pentasubstituted Pyrrolidines by Phenylsulfanyl 
Migration,” Org. Lett., 2002, 4, 4381-4384. 
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12.  Minami, Y.; Yoshida, K.; Azuma, R.; Urakawa, A.; Kawauchi, T.; Otani, T., “Structure 
of Cypemycin, a New Peptide Antibiotic,” Tetrahedron Lett., 1994, 35, 80001-80004.   
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